(HYGS) Selected for 2 Megawatt Energy Storage Facility in Ontario

MISSISSAUGA, Ontario, July 25, 2014  — Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG) (“Hydrogenics” or “the Company”), a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced that it has been selected as a Preferred Respondent by the Independent Electricity System Operator (IESO) for Ontario in its procurement for Grid Energy Storage. This Power-to-Gas project will deliver 2MW of storage capacity and be located in the Greater Toronto Area. Hydrogenics will supply the facility’s next-generation PEM electrolyzers and is partnering with Enbridge Inc. to develop, build and operate the energy storage facility to provide regulation services to the IESO under contract.

“Storage facilities on the grid are a real game changer,” said Bruce Campbell, President and CEO of the IESO in a press release. “Our electricity system was built on the concept that you can’t store large amounts of electricity – we produce electricity at the same time that we consume it. Energy storage projects will provide more flexibility and offer more options to manage the system efficiently.”

Daryl Wilson, CEO of Hydrogenics, added, “We are very excited to have been awarded this Power-to-Gas project, the first of its kind in North America. We have already experienced the positive impact of having a highly visible reference site with E.ON in Germany, and our partnership with Enbridge will make this application an excellent reference site closer to home. We appreciate the leadership of the Ontario Ministry of Energy to invest in clean energy storage technologies and the IESO for providing this platform for energy innovation.”

Today, we continue to prove that our hydrogen-based energy storage technology will transform the energy sector by providing services to grid operators to convert renewable generation when it is not needed into renewable power, fuel or heat when and where it is needed.

About Hydrogenics

Hydrogenics Corporation (www.hydrogenics.com) is a globally recognized developer and provider of hydrogen generation and fuel cell products and services, serving the growing industrial and clean energy markets of today and tomorrow. Based in Mississauga, Ontario, Canada, Hydrogenics has operations in North America and Europe.

Forward-looking Statements

This release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, and under applicable Canadian securities law. These statements are based on management’s current expectations and actual results may differ from these forward-looking statements due to numerous factors, including: our inability to increase our revenues or raise additional funding to continue operations, execute our business plan, or to grow our business; inability to address a slow return to economic growth, and its impact on our business, results of operations and consolidated financial condition; our limited operating history; inability to implement our business strategy; fluctuations in our quarterly results; failure to maintain our customer base that generates the majority of our revenues; currency fluctuations; failure to maintain sufficient insurance coverage; changes in value of our goodwill; failure of a significant market to develop for our products; failure of hydrogen being readily available on a cost-effective basis; changes in government policies and regulations; failure of uniform codes and standards for hydrogen fuelled vehicles and related infrastructure to develop; liability for environmental damages resulting from our research, development or manufacturing operations; failure to compete with other developers and manufacturers of products in our industry; failure to compete with developers and manufacturers of traditional and alternative technologies; failure to develop partnerships with original equipment manufacturers, governments, systems integrators and other third parties; inability to obtain sufficient materials and components for our products from suppliers; failure to manage expansion of our operations; failure to manage foreign sales and operations; failure to recruit, train and retain key management personnel; inability to integrate acquisitions; failure to develop adequate manufacturing processes and capabilities; failure to complete the development of commercially viable products; failure to produce cost-competitive products; failure or delay in field testing of our products; failure to produce products free of defects or errors; inability to adapt to technological advances or new codes and standards; failure to protect our intellectual property; our involvement in intellectual property litigation; exposure to product liability claims; failure to meet rules regarding passive foreign investment companies; actions of our significant and principal shareholders; dilution as a result of significant issuances of our common shares and preferred shares; inability of US investors to enforce US civil liability judgments against us; volatility of our common share price; and dilution as a result of the exercise of options; and failure to meet continued listing requirements of Nasdaq. Readers should not place undue reliance on Hydrogenics’ forward-looking statements. Investors are encouraged to review the section captioned “Risk Factors” in Hydrogenics’ regulatory filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission for a more complete discussion of factors that could affect Hydrogenics’ future performance. Furthermore, the forward-looking statements contained herein are made as of the date of this release, and Hydrogenics undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, unless otherwise required by law. The forward-looking statements contained in this release are expressly qualified by this.

CONTACT: Bob Motz
         Chief Financial Officer
         (905) 361-3660
         investors@hydrogenics.com

         Chris Witty
         Hydrogenics Investor Relations
         (646) 438-9385
         cwitty@darrowir.com

(ACTG) Subsidiary Enters into Settlement & Patent License Agreement with Pregis

Acacia Research Corporation (NASDAQ: ACTG) announced today that its Promethean Insulation Technology LLC subsidiary has entered into a settlement agreement resolving all disputes with Pregis Corporation, Pregis Innovative Packaging Corporation, Innovative Energy, Inc. and Energie Innovation, Inc.

ABOUT ACACIA RESEARCH CORPORATION

Founded in 1993, Acacia Research Corporation (NASDAQ: ACTG) is the industry leader in patent licensing. An intermediary in the patent marketplace, Acacia partners with inventors and patent owners to unlock the financial value in their patented inventions. Acacia bridges the gap between invention and application, facilitating efficiency and delivering monetary rewards to the patent owner.

For more information, visit: www.acaciaresearch.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

(AGEN) First Vaccine Candidate for Malaria is Accepted for EU Regulatory Review

Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, announced that GlaxoSmithKline (NYSE: GSK) has submitted a regulatory application for its malaria vaccine candidate, RTS,S, to the European Medicines Agency (EMA), and it has been accepted for regulatory review. RTS,S contains Agenus’ QS-21 Stimulon^® adjuvant, which is part of GSK’s AS01 proprietary adjuvant system. Adjuvants can enhance the immune response when used in combination with antigens in vaccines.

“RTS,S has the potential to protect hundreds of thousands of children against malaria in Sub-Saharan Africa each year and we are proud to be part of this important program,” said Robert Stein, Chief Scientific Officer of Agenus. “RTS,S represents real progress in the decades of work to develop a malaria vaccine and we are gratified that our adjuvant was a key component.”

Malaria claims over 600,000 lives a year, most of which are children in Sub-Saharan Africa (SSA).¹ Around 90 percent of estimated deaths from malaria occur in SSA and 77 percent of these are in children under the age of five. RTS,S is intended exclusively for use against the Plasmodium falciparum malaria parasite, which is most prevalent in SSA. To date, there is no vaccine available for the prevention of malaria.

Agenus has received a milestone payment for the regulatory submission of RTS,S, and is entitled to receive an additional milestone payment upon approval as well as royalties on product sales. QS-21 Stimulon is also being evaluated in 16 additional vaccine candidates currently undergoing clinical study and is a potential source of capital to help fund development of the company’s checkpoint modulator product candidates.

The Phase 3 RTS,S vaccine program was conducted at 13 African research centers in eight African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria, and Tanzania) and included over 16,000 infants and young children. These data have been included to support the regulatory filing.

The EMA submission is the first step in the regulatory process toward making the RTS,S vaccine candidate available as an addition to existing tools currently recommended for malaria prevention. An effective vaccine for use alongside other measures, such as bed nets and anti-malarial medicines, would represent an advance in malaria control.

If a positive opinion from the EMA is granted, the WHO indicated that a policy recommendation may be possible by the end of 2015. A policy recommendation is a formal review process by WHO designed to assist in the development of optimal immunization schedules for diseases that have a global public health impact, such as malaria.²

A positive opinion from the EMA would also be the basis for marketing authorization applications to National Regulatory Authorities (NRAs) in SSA countries. A review by a European medicines agency is required by the majority of African countries prior to registration of a medicinal product manufactured in Europe. If positive, these regulatory decisions would help pave the way toward the large-scale implementation of the vaccine through African national immunization programs.

Notes to Editors

About RTS,S

• RTS,S is the scientific name given to this malaria vaccine candidate and reflects the composition of this vaccine candidate that also contains the AS01 adjuvant system.³
• RTS,S triggers the body’s immune system to defend against the P falciparum malaria parasite when it first enters the human host’s bloodstream and/or when the parasite infects liver cells.
• The vaccine is designed to prevent the parasite from infecting, maturing and multiplying in the liver, after which time the parasite would re-enter the bloodstream and infect red blood cells, leading to disease symptoms. In the Phase 3 efficacy trial, RTS,S was administered in three doses, one month apart.

About QS-21 Stimulon

Agenus’ flagship adjuvant, QS-21Stimulon adjuvant, is a saponin extracted from the bark of the Quillaja saponaria tree, also known as the soap bark tree, an evergreen tree native to warm temperate central Chile. Agenus’ QS-21 Stimulon has become a key component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases and in several investigational therapeutic vaccines intended to treat cancer and degenerative disorders. QS-21 Stimulon has been widely studied in approximately 50,000 patients. Agenus is generally entitled to receive milestone payments as QS-21 Stimulon containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.

About Agenus

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display^® is used to generate fully human therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus’ heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. The company’s QS-21 Stimulon^® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several candidates in Phase 3 trials. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

1. http://www.who.int/malaria/world_malaria_report_2011/en/index.html.
2. WHO policy recommendations overview found at: http://www.who.int/immunization/policy/en/. Accessed May 2014.
3. The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon^® adjuvant, MPL and liposomes.

Retrocyte Display and Stimulon are registered trademarks of Agenus and its subsidiaries.

Forward-Looking Statement

This press release contains forward-looking statements, including statements regarding potential regulatory activities and timelines, the potential application product candidates containing the Company’s QS-21 Stimulon Adjuvant in the prevention and treatment of diseases, and revenue streams to Agenus in connection therewith. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended March 31, 2014. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus’ business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus’ business and securities, investors should give careful consideration to these risks and uncertainties.

(EGHT) Extends Partnership With Zendesk

8×8, Inc. (NASDAQ:EGHT), a provider of cloud-based unified communications, contact center and collaboration solutions, today announced the availability of a new, out-of-the-box integration with Zendesk’s customer service platform that enhances the Customer Experience Management capabilities of the 8×8 Virtual Office cloud telephony and unified communications (UC) platform.

Businesses today need to provide better customer experiences in order to remain competitive. Inefficient customer interactions not only cost the business more money, they also erode customer relationships. The combined 8×8 and Zendesk solution tightly integrates business telephony and customer relationship functionality to enable organizations to provide more efficient and more personalized interactions with their customers.

“We are excited to be the first cloud UC provider to offer secure and reliable business telephony as well as contact center integration with Zendesk, enabling all companies to conduct better Customer Experience Management,” said 8×8 CEO Vik Verma. “Businesses today who are not optimizing the experience that occurs with each and every customer interaction will certainly enable their competition to be considered for that customer’s next call.”

“Customers expect to be able to reach companies at any time and across any channel or device,” said Sam Boonin, VP Product at Zendesk. “With 8×8 Virtual Office’s integration into Zendesk, the customer not only has these options, but they can also receive the high quality and personal service that they deserve.”

With the Virtual Office integration with Zendesk, incoming calls to a business through the 8×8 Virtual Office phone service instantly triggers a customer’s profile and ticket to appear on the user’s computer screen before the call is answered, allowing the employee to answer the call with all the relevant historical and account data.

The combined solution offers:

• Instant display of a customer profile based upon the Caller ID.
• Click to dial from Zendesk and the 8×8 Virtual Office directory.
• Fortune 500 telephony features and functionality.

“New channels of interaction have given consumers more power, control, and knowledge. Research has shown that customers turn first to the Web and their peers to get information and self-serve before they call into the company or its contact center, changing the balance of power between the agent and customer,” said Nancy Jamison, Principal Analyst, Customer Contact, Frost & Sullivan. “As such, the ability to pull in, combine, and use customer interaction history is the future in providing the elevated level of customer experience new generations of consumers demand.”

The 8×8 Virtual Office cloud communications solution is highly redundant, reliable and secure, offering compliance with many data security standards including FISMA, HIPAA HITECH, PCI-DSS and CPNI.

To learn more about 8×8 Virtual Office and Zendesk integration, visit: http://www.8×8.com/VoIPBusinessPhoneServices/Features/zendeskintegration.aspx.

Existing Zendesk customers can install the Virtual Office App from the Zendesk app store at: https://www.zendesk.com/apps/8×8-virtual-office/.

About 8×8, Inc.

8×8, Inc. (NASDAQ:EGHT) is the trusted provider of secure and reliable cloud-based unified communications and virtual contact center solutions to more than 39,000 small, midsize and distributed enterprise organizations operating in over 40 countries across six continents. 8×8’s out-of-the-box cloud solutions replace traditional on-premise PBX hardware and software-based systems with a flexible and scalable Software as a Service (SaaS) alternative, encompassing cloud business phone service, contact center solutions, and web conferencing. For additional information, visit www.8×8.com, or www.8×8.com/UK or connect with 8×8 on Google+, Facebook, LinkedIn and Twitter.

(QLIK) Introduces Next-Generation Data Visualization and Discovery Application – Qlik Sense

Qlik (NASDAQ: QLIK), a leader in data discovery, today introduced Qlik® Sense Desktop, (www.qlik.com/us/explore/products/qlik-sense/desktop) a free version of its next-generation data visualization application that delivers a simple drag-and-drop interface for business users to rapidly create interactive visualizations, reports, and dashboards. Qlik Sense Desktop is the first commercially available release from the QlikView.Next project. It includes the Qlik patented data indexing engine to give users the unrestricted ability to explore their intuition and the relationships that exist in the data, uncovering the hidden associations and insights that may otherwise be overlooked.

Qlik Sense Desktop delivers an intuitive drag-and-drop user experience for data visualization, exploration, and storytelling capabilities in a standalone, installed Windows client. It allows for the assembly and navigation of visualization apps that can be saved as local files to be shared and opened by other users. Novice users can get started by simply dragging an Excel document right into the application, or by tapping into multiple data sources used within the business. Qlik Sense Desktop is free for personal and business use, with no limits on the number of apps that can be created and no restrictions on file sharing.

The complete Qlik Sense offering, expected to be generally available in September 2014, will be server-based enabling server side development from any device, flexible mobile use, collaboration and sharing, custom development and data integration. It will also have key enterprise capabilities, data security, and data and application governance. All Qlik Sense offerings index the data to allow users to immediately begin exploring and visualizing data.

“Qlik Sense Desktop is a great way to show people who are new to Qlik the power and control you can feel by exploring your own data to make it meaningful, visual, and even fun. Our continued commitment to simplicity and ease of use to put users in control is delivering on the promise of true self-service BI,” said Anthony Deighton, Qlik CTO and Senior Vice President of Products.

Capabilities of Qlik Sense Desktop include:

• Multiple data sources from simple Excel files to ODBC accessible databases can easily be brought into the Qlik Sense app.
• Drag-and-drop dashboard creation in minutes to build or extend visual analysis.
• Explore, associate, and combine information in new ways not possible in other products without starting over to create a new visualization. Because it is powered by the Qlik data indexing engine and associative experience, users can dynamically explore and ask any question.
• Smart Search to simply type words or numbers to begin analysis of the entire data set.
• Intuitive Smart Visualizations offer cues to help novices explore patterns by dynamically updating and highlighting new information and associations.
• Data Storytelling to capture insights and share at a point in time in presentation format. Users can add commentary and narrative and drill down directly from the presentation to Qlik Sense data to answer questions on the fly.

In addition to offering Qlik Sense for interactive visualization, Qlik will continue to offer its market-proven platform, QlikView, to provide application development that enables analysts with minimal development expertise to build and publish powerful analytical applications.

“QlikView brought BI out of the back-office, and into the front lines of business, as analysts created powerful guided analytics for every conceivable business process,” said Rick Jackson, Qlik CMO. “With Qlik Sense, we now address the widespread desire for rapid data visualization, dashboards, and visual reporting. This combination provides businesses with broader access to data visualization and discovery that can be leveraged to improve both top-line and bottom-line results for any company.”

About Qlik

Qlik (NASDAQ: QLIK) is a leader in data discovery delivering intuitive solutions for self-service data visualization and guided analytics. Approximately 32,000 customers rely on Qlik solutions to gain meaning out of information from varied sources, exploring the hidden relationships within data that lead to insights that ignite good ideas. Headquartered in Radnor, Pennsylvania, Qlik has offices around the world with more than 1700 partners covering more than 100 countries.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the value and effectiveness of Qlik’s products, the introduction and timing of product enhancements or additional products and Qlik’s growth, expansion and market leadership, that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Qlik’s results to differ materially from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “predicts,” “plan,” “expects,” “focus,” “anticipates,” “believes,” “goal,” “target,” “estimate,” “potential,” “may,” “will,” “might,” “momentum,” “can,” “could,” “seek,” and similar words. Qlik intends all such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in such statements due to various factors. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent Qlik’s views as of the date of this press release. This press release is intended to outline our general product direction and should not be relied on in making a purchase decision, as the development, release, and timing of any features or functionality described for our products remains at our sole discretion. Qlik anticipates that subsequent events and developments will cause its views to change. Qlik undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Qlik’s views as of any date subsequent to the date of this press release.

© 2014 QlikTech International AB. All rights reserved. Qlik®, Qlik® Sense, QlikView®, QlikTech®, and the QlikTech logos are trademarks of QlikTech International AB which have been registered in multiple countries. Other marks and logos mentioned herein are trademarks or registered trademarks of their respective owners

(VGGL) Study Finds Viggle Improves TV Ad Effectiveness

Viggle Inc. (NASDAQ:VGGL) (“Viggle”), the entertainment marketing and rewards platform today has released findings from its “Brand Effect Study” showing that exposure to TV advertisements seen on both television and the Viggle app resulted in higher brand recall. The study concluded that Brand and Message Recall, Likeability, and Purchase Intent were higher for a campaign that took place in May, as a result of a TV advertising buy being extended to Viggle’s platform.

“This study demonstrates that when a brand establishes a second screen media presence via the Viggle platform in conjunction with its TV spend, it drives higher awareness, stronger message recall and greater purchase intent among its key consumers,” said Kevin Arrix, Chief Revenue Officer of Viggle. “Furthermore, while we address this as ‘second screen’, it’s worth noting that mobile device usage, while the television is on, is de facto in today’s household. In order to ensure getting the in-home consumer’s attention, brands have to distribute their messaging on both the TV and the mobile device.”

As part of the commissioned study, Nielsen surveyed three groups of Viggle members that were defined as TV Only Exposed, Viggle Only Exposed and TV and Viggle Exposed. Those that watched and checked into a TV show where the ad aired, but were not served the ad in the app were defined as TV Only Exposed. A verified check in occurs when Viggle’s patented technology confirms that a user is watching a particular program by sampling and accurately matching the audio. Users that did not check into or watch a TV show where the ad aired, but had the opportunity to view the ad on Viggle were determined as Viggle Only Exposed. TV and Viggle Exposed users were Viggle users that watched and checked into a TV show where the ad aired and were also served the ad in the Viggle app.

Key findings from the study found that dual exposure to the ad on both TV and within the Viggle platform boosted resonance, resulting in a 39% increase in brand recall among TV and Viggle Exposed users (46%) versus TV Only Exposed users (33%). Dual exposure also yielded a significant uptick in likeability and interest in the creative with users expressing interest to purchase. The 20% of TV and Viggle Exposed users who were interested in purchasing the product seen in the advertisement was nearly double the number of TV Only users (12 %), who felt similarly.

Other key findings from the study include:

• Forty percent of TV and Viggle users were able to recall the ad, brand and message of the TV ad in comparison to 25% of TV Only users
• Positive Likeability was higher among TV and Viggle users at 46% compared to 37% among TV Only users
• Once respondents recalled the ad, 87% of TV and Viggle exposed users were able to recall the correct brand compared to 79% of TV Only users

About Viggle

Viggle is an entertainment marketing and rewards platform whose app rewards its members for watching TV shows and discovering new music. The Viggle mobile app has over 5 million users. Since its launch, Viggle members have redeemed nearly $19 million in rewards for watching their favorite TV programs and listening to music. Members can also use The Viggle Store, a rewards destination where they can redeem their Viggle Points for music downloads. In addition, Viggle operates Wetpaint, which offers entertainment and celebrity news online; Dijit Media, maker of technology that helps consumers search for, find, and set reminders for TV shows and movies; and Choose Digital, a digital marketplace platform that allows companies to incorporate digital content into existing rewards and loyalty programs in support of marketing and sales initiatives. For more information, visit www.viggle.com or follow us on Twitter @Viggle.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. All information provided in this press release is as of the date of this release. Except as required by law, Viggle Inc. undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

(OPHC) Announces Continued Listing on NASDAQ

FORT LAUDERDALE, Fla., July 24, 2014 — OptimumBank Holdings, Inc. (Nasdaq:OPHC), the parent company of OptimumBank (“Company”), announces that it has regained compliance with NASDAQ minimum shareholders’ equity rule per NASDAQ Listing Qualification Notice dated July 14, 2014. The Company will continue to be listed on NASDAQ.

The Company completed the sale of 755,286 shares since March 31, 2014 for an aggregate amount of $841,000 by July 1, 2014. Completion of these sales, together with the Company’s estimated net income for the fiscal quarter ended June 30, 2014, will cause shareholders’ equity to exceed the $2.5 million minimum threshold for NASDAQ listing. In addition, the Company has successfully demonstrated the ability to sustain that level going forward.

Chairman Gubin said, “We are pleased to announce the successful resolution of this matter and the continued listing of the Company’s shares on the NASDAQ Capital Market. Following this positive development, we continue to focus on implementing our business plan for continued earnings improvement. The NASDAQ listing notification continues a string of events that highlight the Company’s successful turnaround efforts.” Mr. Gubin added, “The continued listing on NASDAQ is important for strengthening our investor confidence as it demonstrates our commitment to provide them with a securities exchange platform for liquidity and transparency.”

This press release includes forward-looking statements and OptimumBank Holdings, Inc. intends for such statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements describe OptimumBank Holdings, Inc.’s expectations regarding future events.  Future events are difficult to predict and are subject to risk and uncertainty which could cause actual results to differ materially and adversely. OptimumBank Holdings, Inc. undertakes no obligation to revise or amend any forward-looking statements to reflect subsequent events or circumstances. 

CONTACT: Moishe Gubin, Chairman of the Board,
         or Thomas Procelli, Chief Operating Officer,
         at (954) 900-2800

(GRH) Schedules Q2 2014 Results Conference Call: August 4, 2014

GreenHunter Resources, Inc. (NYSE MKT: GRH) (NYSE MKT: GRH.PRC), a diversified water resource, waste management, environmental services, and hydrocarbon marketing company specializing in the unconventional oil and natural gas shale resource plays, announced today that it has scheduled its quarterly conference call to discuss its second quarter and YTD 2014 financial and operating results. The scheduled conference call will occur on Monday, August 4, 2014, at 9:00 a.m. CDT. The Company will issue a press release announcing these financial and operating results before the U.S. financial markets open on the morning of the conference call. On the conference call, senior management will discuss these financial and operating results, two new recently established operating divisions, anticipated capital expenditures for the remainder of 2014, the announcement of the intent to form a MLP, as well as other corporate related matters.

Individuals who would like to participate should call (866) 900-8550 (Conference ID: 78846849) approximately 15 minutes before the scheduled conference call time. An audio recording of this conference call will be posted on the Company’s website, www.greenhunterresources.com, under “Investors” following the call, and will be available for 12 months. The Company’s quarterly report on Form 10-Q for three months ended June 30, 2014, to be filed with the Securities and Exchange Commission (SEC), will also be available on our website under “Investors,” upon filing with the SEC.

About GreenHunter Resources, Inc.

GreenHunter Resources, Inc., through its wholly-owned subsidiaries, GreenHunter Water, LLC, GreenHunter Environmental Solutions, LLC, and GreenHunter Hydrocarbons, LLC, provides Total Water Management Solutions™/Oilfield Fluid Management Solutions™ in the oilfield and its shale plays of the Appalachian Basin. GreenHunter Water continues to expand its services package by increasing down-hole injection capacity with Class II salt water disposal wells and facilities, with the launch of next-generation modular above-ground frac water storage tanks (MAG Tank™), and with advanced water hauling – including a growing fleet of DOT rated 407 trucks, for hauling condensates and water with the presence of condensates. GreenHunter Water has also spearheaded the movement to barge brine water, as barging is the safest and most cost-effective mode of transport.

GreenHunter Environmental Solutions, LLC offers onsite environmental solutions at the well pad and facilities, with a service package that includes tank and rig cleaning, liquid and solid waste removal/remediation, solidification, and spill response. An understanding that an interconnected suite of services is key to E&P waste stream management shapes GreenHunter Resources’ comprehensive end-to-end approach to services.

GreenHunter Hydrocarbons, LLC offers transportation of hydrocarbons (oil, condensate, and NGLs) and will soon offer storage, processing, and marketing of hydrocarbons (oil, condensate, and NGLs) in the Appalachian region, leveraging off of our existing asset base and infrastructure, which includes up to six different barge terminal locations, presently owned or leased by GreenHunter Resources.

For a visual animation of the Class II Salt Water Disposal well development and completion technique that is being utilized in GreenHunter Water’s Appalachia SWD program, navigate to the video by clicking on “Salt Water Disposal Animation” button on the Operations tab at GreenHunterEnergy.com or click here.

Additional information about GreenHunter Water may be found at www.GreenHunterWater.com.

Forward-Looking Statements

Any statements in this press release about future expectations and prospects for GreenHunter Resources and its business and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the substantial capital expenditures required to fund its operations, the ability of the Company to implement its business plan, government regulation and competition. GreenHunter Resources undertakes no obligation to update these forward-looking statements in the future.

(LGND) GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (GSK) plc has announced global revenue for Promacta™/Revolade™ for the second quarter ended June 30, 2014 of $92 million, up 31% from the second quarter of 2013. United States, European Union and the Emerging Markets all reported double-digit growth over the prior quarter, with United States up 17% and Emerging Markets up 50% versus first quarter 2014.

“Promacta continues to illustrate its value and importance in addressing major unmet medical needs,” said John Higgins, President and CEO of Ligand Pharmaceuticals. “GSK has maintained a global view of brand management and an ongoing commitment to maximizing the reach of Promacta/Revolade to patients in need. These impressive quarterly results clearly underscore GSK’s commitment to the product and represent the highest quarterly sales in the history of the drug and largest quarter-over-quarter growth in dollars.”

Recent Events Relating to Promacta/Revolade

In addition to quarterly global revenue for Q2 2014, GSK has also recently announced a number of other milestones or data events relating to Promacta/Revolade, including:

• Receipt of both Breakthrough Therapy Designation and Priority Review status for a supplemental New Drug Application (sNDA) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy. SAA is a rare disorder in which the bone marrow fails to make enough new blood cells. There are no approved therapies available for SAA patients who are unresponsive to initial immunosuppressive therapy (IST).

• Results of the Phase 3 PETIT2 study evaluating the efficacy of eltrombopag versus placebo in pediatric patients with chronic idiopathic thrombocytopenic purpura (cITP). The study met its primary endpoint, and GSK announced that it is moving forward with planned global regulatory submissions for a pediatric indication in cITP in 2014.
• Initiation of the global Phase 3 SUPPORT trial to evaluate the platelet supportive care effects of eltrombopag in combination with azacitidine (the current standard of care) versus placebo in combination with azacitidine in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes (MDS). The study will assess the proportion of patients who do not require a platelet transfusion during the first four cycles of treatment.
• GSK and Novartis AG announced that Novartis is acquiring GSK’s oncology portfolio, including Promacta/Revolade, for an aggregate cash consideration of $16 billion, a sales multiple of approximately 10 times 2013 revenue. The deal leverages Novartis’ commercial capabilities in oncology, and Novartis projects significant growth over the coming years for the brands, including Promacta. The transaction is expected to be complete by the first half of 2015, subject to approvals.

About Eltrombopag (Promacta/Revolade)

Eltrombopag – marketed as Promacta^™ in the U.S. and as Revolade^™ in Europe and other countries around the world – works by interacting with the TPO receptor leading to increased platelet production. Eltrombopag is not approved or licensed anywhere in the world for use in patients with myelodysplastic syndromes.

For full U.S. Prescribing Information for Promacta^® (eltrombopag), including Boxed Warning, please visit here. For the European Union (EU) Summary of Product Characteristics (SPC) for Revolade^® (eltrombopag) in approved indications, please visit here.

Promactaand Revoladeare trademarks of the GSK group of companies.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying our portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world’s leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com. Follow Ligand on Twitter @Ligand_LGND.

Forward-Looking Statements

This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. These forward-looking statements include comments regarding eltrombopag, data analysis and evaluation of eltrombopag, utility or potential benefits to patients, the potential commercial market for eltrombopag and plans for continued development and further studies of eltrombopag. Actual events or results may differ from Ligand’s expectations. For example, there can be no assurance that other trials or evaluations of eltrombopag will be favorable or that they will confirm results of previous studies, that data evaluation will be completed or demonstrate any hypothesis or endpoint, that eltrombopag will provide utility or benefits to certain patients, that any presentations will be favorably received, that eltrombopag will be useful, that marketing applications will be filed or, if filed, approved, or that clinical or commercial development of eltrombopag will be initiated, completed or successful or that our rights to eltrombopag will not be successfully challenged. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand’s stock price. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in public periodic filings with the Securities and Exchange Commission, available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this press release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

(ADK) Announces Strategic Plan to Transition to a Facilities Holding Company

New Business Model Designed To Optimize Cash Flow and Unlock Shareholder Value Conference Call to Discuss Transition Scheduled for July 24, 2014 at 10 a.m.

ATLANTA, July 23, 2014  — AdCare Health Systems, Inc. (NYSE MKT: ADK) (NYSE MKT: ADK.PRA), a recognized provider of senior living and healthcare facility management, today announced that the Board of Directors has approved, and management has begun to implement, a strategic plan to transition the Company to a healthcare property holding and leasing company. Through a series of leasing transactions, the operations of the Company’s currently owned and operated healthcare facilities, which are principally skilled nursing facilities, will be transitioned to third parties, and the properties AdCare leases will be sub-leased. The Board of Directors believes this new business model will help the Company unlock shareholder value by reducing risk, enhancing cash flow and enabling the Company to return cash to shareholders through a quarterly dividend.

“Over the last several months, the Board of Directors has actively evaluated a number of strategic alternatives to unlock long-term shareholder value, including a possible sale of the Company,” stated David Tenwick, AdCare’s Chairman and Interim Chief Executive Officer.  “It became clear that the Company’s historical structure as an owner/operator was not conducive to maximizing value. The Board identified several elements of the business model which inhibited the Company’s ability to maximize the value of its assets. These elements included high ongoing G&A expenses, execution risk, and the fact that potential REIT buyers would have to find operators to manage all of AdCare’s properties. These factors reduced the number of potential parties interested in acquiring all or part of the Company, and resulted in valuations that the Board considered unacceptable. After careful analysis and consideration, the Board unanimously agreed to exit the day-to-day management of our healthcare facilities and begin transitioning the Company to a healthcare property holding and leasing company. This structure requires significant less working capital enabling the Company to begin returning cash to shareholders through an increasing quarterly dividend, commencing in the near term, while allowing the company to pursue strategic acquisitions, and the Board firmly believes this structure will ultimately maximize shareholder value.”

Under the strategic plan, the Company will execute a series of leasing transactions by which it will lease the operations of its currently owned and operated healthcare properties, and sub-lease properties the Company currently leases, to third parties, effectively exiting the operations of these facilities, and will transition its business to the ownership, acquisition and leasing of healthcare-related properties. The Company has identified and commenced discussions with regional operators to lease its facilities in Ohio, Oklahoma and Arkansas, representing 18 of the Company’s 34 facilities. Furthermore, certain regional operators in other markets, including Alabama, Georgia and South Carolina, have contacted the Company to discuss leasing the Company’s facilities in these regions.

The Company has scheduled a special meeting of shareholders to be held on October 14, 2014, at which it will seek shareholder approval of certain of the leasing transactions to the extent such approval may be required under Georgia law.

AdCare’s Strategic Priorities Include:

• Seeking free cash flow and dividend yield rather than revenue growth.
• Decreasing financial leverage to lower the cost of capital, reducing outstanding debt and associated interest expense, and releasing cash collateral.
• Returning cash to shareholders through increasing quarterly dividend payments on the common stock resulting in an attractive dividend yield.
• Made available to the Company additional strategic alternatives at improved valuations.

Anticipated Next Steps Under the Strategic Plan:

• Negotiate and execute lease agreements with healthcare operators for all 34 properties in the current portfolio. Leases are expected to be executed on a “triple net” basis, designating the operators as solely responsible for all costs relating to the property, in addition to the lease payments.
• Hold a special meeting of shareholders, scheduled for October 14, 2014, to seek shareholder approval of certain of the leasing transactions to the extent such approval may be required under Georgia law.
• The Board plans to initiate a quarterly dividend payment on the common stock, expected to be $0.05 per common share, to be declared by the Board as soon as the fourth quarter of 2014 and paid in the first quarter of 2015. The Company expects to methodically increase the quarterly dividend payments at a targeted rate of $0.01 per share each quarter for the forseeable future.
• Pursue alternative financing options in order to revamp the Company’s capital structure, reduce financing costs and increase flexibility.
• Potentially grow and diversify the existing portfolio of properties over time by acquiring additional properties in different markets, also to be leased to local and regional healthcare providers.

Under the Strategic Plan, the Company Expects:

• Revenue will be generated primarily by lease payments from the operators of the facilities.
• Through headcount reductions and other expense-reducing efforts, G&A will be significantly reduced.
• A significant improvement in earnings before taxes.
• Existing net operating losses of approximately $25.8 million will be available to offset future taxable income.

Pro Forma Selected Financial Information
The table below compares selected financial information for 2013 actual results to the new model, which adjusts 2013 results as if all facilities were leased.

(Amounts in Millions)

See “Use of Non-GAAP Financial Information”  below for the definition of Adjusted EBITDAR from continuing operations, a non-GAAP financial measure, as well as an important discussion about the use of this measure and its reconciliation to GAAP net loss, the most directly comparable GAAP financial measure.

“This transition should immediately increase the visibility and predictability of our business and remove significant execution risk,” added Ron Fleming, AdCare’s Chief Financial Officer. “In addition, through refinancing efforts and the benefit of lower interest rates due to beneficial attributes of our new business model, we expect to lower our cost of capital over the next several quarters, improving earnings before income taxes.”

Advisors
SunTrust Robinson Humphrey served as financial advisor to the Company in its recent review of a possible sale of the Company and provided certain assistance to the Company in its evaluation of strategic alternatives. Rogers & Hardin LLP is serving as the Company’s outside legal counsel in connection with these matters.

Conference Call and Webcast
AdCare will hold a conference call to discuss its plan on Thursday, July 24, 2014 at 10a.m., Eastern Time. Management will host a presentation, followed by a question and answer period.

• Time: 10 a.m., Eastern Time
• Date: Thursday, July 24, 2014
• Dial-in: 1-888-417-8533 (domestic) or 1-719-457-2085 (international)
• Slides: Management will provide slides to accompany the prepared comments. Slides will be available on the webcast, or can be downloaded in the investor relations section of AdCare’s website at www.adcarehealth.com.
• Webcast: http://public.viavid.com/index.php?id=110136

Important Additional Information to be Filed With the Securities and Exchange Commission
This press release may be deemed to be solicitation material in respect of the proposed shareholder vote to be held at the Company’s special meeting of shareholders scheduled for October 14, 2014. In connection with the special meeting, the Company intends to file with the Securities and Exchange Commission a proxy statement and other relevant materials. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING, WHEN AVAILABLE, THE DEFINITIVE PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSALS PRESENTED AT THE SPECIAL MEETING.  The definitive proxy statement (when available) will be mailed to shareholders of the Company.  Shareholders will be able to obtain, without charge, a copy of the definitive proxy statement (when available) and other documents that the Company files with the Securities and Exchange Commission from the Securities and Exchange Commission’s website at www.sec.gov.  The definitive proxy statement (when available) and other relevant documents will also be available, without charge, by directing a request by mail or telephone to AdCare Health Systems, Inc.,  Attn: Corporate Secretary, at 1145 Hembree Road Roswell, Georgia 30076 or (678) 869-5116, or from the Company’s website, www.adcarehealth.com.

The Company and its directors and executive officers and certain other members of its management and employees may be deemed to be participants in the solicitation of proxies in connection with the special meeting.  ADDITIONAL INFORMATION REGARDING THE INTERESTS OF SUCH POTENTIAL PARTICIPANTS WILL BE INCLUDED OR INCORPORATED BY REFERENCE IN THE DEFINITIVE PROXY STATEMENT (WHEN AVAILABLE).

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE MKT: ADK) (NYSE MKT: ADK.PRA) is a recognized provider of senior living and health care facility management. Since the Company’s inception in 1988, it has owned and managed long-term care facilities and retirement communities,and has sought to provide the highest quality of healthcare services to the elderly through its operating subsidiaries, including a broad range of skilled nursing and sub-acute care services. The Company has implemented a strategic plan pursuant to which, through a series of leasing transactions, it will transition from an owner and operator of healthcare facilities to a healthcare property holding and leasing company. For more information about AdCare, visit www.adcarehealth.com.

Use of Non-GAAP Financial Information
Beginning with the reporting of results for the first quarter of 2011, the Company began to report the measures of Adjusted EBITDA from continuing operations and Adjusted EBITDAR from continuing operations. These are measures of operating performance that are not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). The Company defines: (i) “Adjusted EBITDA from continuing operations ” as net income (loss) from continuing operations before interest expense, income tax expense; depreciation and amortization (including amortization of non-cash stock-based compensation), acquisition costs (net of gains), loss on extinguishment of debt, derivative loss or gain and other non-routine adjustments; and (ii) “Adjusted EBITDAR from continuing operations” as net income (loss) from continuing operations before interest expense; income tax expense, depreciation and amortization (including amortization of non-cash stock-based compensation), acquisition costs (net of gains), loss on extinguishment of debt, derivative loss or gain, rent and other non-routine adjustments.

Adjusted EBITDA from continuing operations and Adjusted EBITDAR from continuing operations should not be considered in isolation or as a substitute for net income, income from operations or cash flows provided by, or used in, operations as determined in accordance with GAAP. Adjusted EBITDA from continuing operations and Adjusted EBITDAR from continuing operations are used by management to focus on operating performance and management without mixing in items of income and expense that relate to the financing and capitalization of the business, fixed rent or lease payments of facilities, derivative loss or gain, and certain acquisition related charges and other non-routine adjustments.

The Company believes these measures are useful to investors in evaluating the Company’s performance, results of operations and financial position for the following reasons:

• They are helpful in identifying trends in the Company’s day-to-day performance because the items excluded have little or no significance to the Company’s day-to-day operations;
• They provide an assessment of controllable expenses and afford management the ability to make decisions which are expected to facilitate meeting current financial goals as well as achieve optimal financial performance; and
• They provide data that assists management to determine whether or not adjustments to current spending decisions are needed.

AdCare believes that the use of the measures provides a meaningful and consistent comparison of the Company’s underlying business between periods by eliminating certain items required by GAAP, which have little or no significance in the Company’s day-to-day operations.

Important Cautions Regarding Forward-Looking Statements
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such statements can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “intends,” “anticipates” and variations of such words or similar expressions, but their absence does not mean that the statement is not forward-looking. Statements in this announcement that are forward-looking include, but are not limited to: (i) statements regarding the strategic plan to transition the Company to a healthcare property holding and leasing company; (ii) statements regarding expense reductions, alternative financing options, reduced financing costs, run-rates and improved valuations; (iii) statements regarding anticipated dividend payments; (iv) statements regarding additional strategic alternatives; (v) statements regarding financial and operational improvements; and (vi) statements regarding the outlook for financial metrics. Such forward-looking statements reflect management’s beliefs and assumptions and are based upon information currently available to management and involve known and unknown risks, results, performance or achievements of AdCare, which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by AdCare with the Securities and Exchange Commission and include, among others, AdCare’s ability to secure lines of credit and/or an acquisition credit facility, AdCare’s ability to refinance its current debt on more favorable terms, AdCare’s ability to expand its borrowing arrangement with certain existing lenders, AdCare’s ability to raise equity capital, AdCare’s ability to improve operating results, changes in the health care industry because of political and economic influences, changes in regulations governing the health care industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There is no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements. Except where required by law, AdCare undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

In addition, each facility mentioned in this press release is operated by a separate, wholly owned, independent operating subsidiary that has its own management, employees and assets.
References to the consolidated Company and its assets and activities, as well as the use of terms such as “we,” “us,” “our,” and similar verbiage, is not meant to imply that AdCare Health Systems, Inc. has direct operating assets, employees or revenue or that any of the facilities, the home health business or other related businesses are operated by the same entity.

(FTNT) First to Deliver 1 Terabit Per Second Firewall Throughput

Fortinet® (NASDAQ:FTNT), a global leader in high-performance network security, today redefined the standard for firewall performance by being the first network security vendor to deliver a firewall – the new FortiGate 5144C – that exceeds 1 terabit per second (Tbps) throughput performance and offers 10GbE, 40GbE and 100GbE connectivity options. This firmly positions the FortiGate 5144C as the world’s fastest firewall, making it the ideal security solution for carriers, service providers and large-scale enterprises who have the most demanding performance and scalability requirements for network security, and who want unparalleled versatility and flexibility in delivering high-performance data, application and network protection to their customers and users.

“Major market drivers, such as big data, cloud-based services and the explosion of Software as a Service translates to data centers needing exceptionally fast and secure security platforms to protect their applications and data,” said Ken Xie, founder and CEO of Fortinet. “Others have claimed to have the fastest firewall, but no other vendor has actually delivered this level of performance and security, which enables customers to build out their data centers for the future, knowing that their firewalls will not be a choke point.”

FortiGate 5000 Series – Setting the Standard for High-Performance Security via NP6 ASICs

The new FortiGate 5000 Series is Fortinet’s flagship, chassis and blade firewall platform. Built for large-scale enterprise data center and carrier-class environments, the FortiGate 5000 series includes fully redundant, hot-swappable power supplies, fans and firewall blades for maximum uptime.

The new 5000 Series is comprised of a new chassis – the FortiGate 5144C, controller networking blades (5903C/5913C) and security blades (5001D) that utilize the latest NP6 network processor to deliver 40 Gbps firewall throughput per ASIC. Unlike common, off-the-shelf processors used by other vendors, the NP6 ASIC is a revolutionary, low-power design that produces unparalleled firewall throughput (40Gbps) and ultra-low latency. Coupled with native IPv4 and IPv6 traffic processing, the NP6 is ideally suited for next-generation networks. By running fourteen 5001D security blades concurrently, today’s 5000 Series delivers more than 1 Tbps firewall throughput.

The new 5000 Series leverages the same high-performance hardware architecture, NP6 ASICs and FortiOS that power the award-winning enterprise FortiGate 1000 and 3000 security appliances that protect data centers and enterprise users. This provides unparalleled deployment flexibility, security functionality and policy enforcement.

“The industry is facing a massive change as businesses and consumers demand applications and services to be delivered instantly. Just as important is the fact that security must play an active role in this new paradigm of delivering X-as-a-service,” said Chris Rodriguez, senior industry analyst, network security at Frost & Sullivan. “By delivering firewall performance at the one terabit per second threshold, Fortinet helps ensure new services can be added into the future and delivered without sacrificing security or performance.”

FortiGate 5001D Blades – State of the Art Security in a Blade Design

The new 5001D security blades provide the core security capabilities to the new 5000 Series. These represent the 5^th generation process boards that can process 80 Gbps throughput. Each 5001D blade embeds two FortiASIC NP6 processors. This provides full next-generation firewall capabilities, including: deep packet inspection, IPS, application control, web content filtering and more. In addition, because of Fortinet’s unique VDOM technology, multiple virtual instances can run concomitantly, giving MSSPs and carriers the ability to offer thousands of dedicated NGFW capabilities to their customers.

“Operating one of the largest end-to-end communications networks in the United States requires high performance and strong security,” said Mike Perusse, CTO of MegaPath, a nationwide provider of voice, data, security and cloud services. “Fortinet is a clear leader of high-performance network security, and their new 5000 Series stands to be a breakthrough in helping to secure the delivery of next-generation services, today.”

New FortiController to Provide 100 Gigabit Ethernet Connectivity

For data centers or telecom environments that require 100 Gigabit Ethernet connectivity, Fortinet presents the new FortiController-5913C controller blade. The FortiController-5913C is an Advanced Telecommunications Computing Architecture (ATCA) compliant session-aware load balancing hub/switch that distributes traffic amongst the new FortiGate-5001D blades within the 5000-series chassis fabric backplane. This provides unparalleled performance and eliminates any potential bottlenecks as data centers re-architect their network topology to 100 GbE. Optionally, customers can use the FortiController-5903C in environments that need 40 Gigabit Ethernet connectivity.

Availability

The new FortiGate 5000 Series – complete with the new 5144C Chassis, 5903C Controller and 5001D security blades are available this quarter from authorized Fortinet channel partners. The FortiController-5913C will be available in Q4. For more information about FortiGate products, please visit: http://www.fortinet.com/products/fortigate/index.html, or view the new FortiGate online demo at: http://www.fortinet.com/resource_center/product_demo_center.html.

About Fortinet

Fortinet (NASDAQ: FTNT) helps protect networks, users and data from continually evolving threats. As a global leader in high-performance network security, we enable businesses and governments to consolidate and integrate stand-alone technologies without suffering performance penalties. Unlike costly, inflexible and low-performance alternatives, Fortinet solutions empower customers to embrace new technologies and business opportunities while protecting essential systems and content. Learn more at www.fortinet.com.

Copyright © 2014 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and unregistered trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, FortiGate, FortiGuard, FortiManager, FortiMail, FortiClient, FortiCare, FortiAnalyzer, FortiReporter, FortiOS, FortiASIC, FortiWiFi, FortiSwitch, FortiVoIP, FortiBIOS, FortiLog, FortiResponse, FortiCarrier, FortiScan, FortiAP, FortiDB, FortiVoice and FortiWeb. Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties, and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, binding specification or other binding commitment by Fortinet, and performance and other specification information herein may be unique to certain environments. This news release contains forward-looking statements that involve uncertainties and assumptions. Changes of circumstances, product release delays, or other risks as stated in our filings with the Securities and Exchange Commission, located at www.sec.gov, may cause results to differ materially from those expressed or implied in this press release. If the uncertainties materialize or the assumptions prove incorrect, results may differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Fortinet assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to update these forward-looking statements.

(BIIB) PLEGRIDY™ Approved in the EU for the Treatment of Multiple Sclerosis

Today Biogen Idec (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY^TM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe.

“PLEGRIDY offers people living with MS an interferon with compelling efficacy that requires considerably fewer injections than other platform therapies,” said George A. Scangos, Ph.D., chief executive officer at Biogen Idec. “The approval of PLEGRIDY demonstrates our commitment to improving the lives of patients by providing innovative therapies that meet their individual needs, including flexibility in managing their disease.”

PLEGRIDY, the only pegylated interferon approved for use in RRMS, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression.

The EC approval of PLEGRIDY is based on results from one of the largest pivotal studies of a beta interferon conducted, ADVANCE¹, which involved more than 1,500 patients with relapsing forms of MS.

In the ADVANCE clinical trial, PLEGRIDY, dosed once every two weeks, significantly reduced annualized relapse rate (ARR) at one year by 36 percent compared to placebo (p=0.0007).

PLEGRIDY reduced the risk of sustained disability progression confirmed at twelve weeks by 38 percent (p=0.0383) and at twenty four weeks by 54 percent (p=0.0069, post-hoc analysis). In addition, the number of gadolinium-enhancing [Gd+] lesions was significantly reduced by 86 percent (p<0.0001) compared to placebo.

Results over two years of ADVANCE confirm that its robust efficacy was maintained beyond the placebo-controlled first year of the study.

“The safety and efficacy that PLEGRIDY has demonstrated, combined with its less frequent dosing schedule offers MS patients an option to put their treatment in the background for longer stretches of time,” said Professor Bernd C. Kieseier, M.D., Heinrich-Heine Universität, Dusseldorf.

The safety and tolerability profile of peginterferon beta-1a observed in ADVANCE¹ was consistent with that of established MS interferon therapies. The most commonly reported adverse drug reactions with peginterferon beta-1a treatment (incidence ≥10% and at least 2% more frequent on peginterferon beta-1a than on placebo) were injection site reaction, flu-like illness, fever, headache, muscle pain, chills, injection site pain, weakness, injection site itching, and joint pain.¹

PLEGRIDY is the fifth therapy to be offered by Biogen Idec to people living with MS, expanding on a portfolio that addresses individual patient needs.

For more information on PLEGRIDY, visit biogenidec.com. Additional resources on PLEGRIDY are available for the media upon request.

About PLEGRIDY™

PLEGRIDY is a subcutaneous injectable therapy for relapsing-remitting multiple sclerosis (RRMS), in which interferon beta-1a is pegylated to extend its half-life to permit a less frequent dosing schedule. PLEGRIDY is a member of the interferon class of treatments for MS.

According to the EU Summary of Product Characteristics (SmPC), the recommended starting dose of PLEGRIDY is 63 micrograms at dose 1, increasing to 94 micrograms at dose 2, reaching the full dose of 125 micrograms by dose 3 and continuing with the full dose (125 micrograms) every 2 weeks thereafter.

The safety and tolerability profile of PLEGRIDY observed in ADVANCE¹ was consistent with that of established MS interferon therapies. PLEGRIDY should be administered with caution to patients with previous depressive disorders, seizures, severe hepatic impairment and severe renal impairment. Cytopenias, including rare severe neutropenia and thrombocytopenia, have been observed in patients treated with PLEGRIDY. The following have been reported with interferon beta medicinal products including PLEGRIDY: Elevations in hepatic enzymes, serious hypersensitivity reactions, injection site reactions with subcutaneous administration, including injection site necrosis, and worsening of cardiac disease.

In addition, the EU SmPC indicates that the use of interferon beta products is associated with cases of nephrotic syndrome, thrombotic microangiopathy manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS), hyper and hypothyroidism, hepatitis, autoimmune hepatitis, rare cases of severe hepatic failure, and decreased peripheral blood counts, including rare pancytopenia.

About Pegylation

Pegylation prolongs the circulation time of the molecule in the body by increasing its size, thus enabling a longer half-life, stabilizing the molecule by improving its solubility and shielding the molecule from enzymes in the body that try to break it down into smaller particles.³ Pegylation is a well-established scientific process that has been used for more than 20 years.^2,3

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system, which is made up of the brain, spinal cord and optic nerves. Symptoms may be mild or severe, ranging from numbness in the limbs to paralysis or loss of vision. The progression, severity and specific symptoms of MS are unpredictable and vary from one person to another. MS affects more than 2.3 million people worldwide,⁴ with more than 600,000 sufferers in the European Union.⁵ Relapsing-remitting MS (RRMS) is the most common form of MS accounting for 85 percent of cases. It is characterized by clearly defined acute attacks with full recovery or with residual deficit upon recovery.⁶

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.

Safe Harbor

This press release contains forward-looking statements, including statements about the potential benefits of PLEGRIDY and the expected timing of commercial launch in the EU. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of success in commercialization of PLEGRIDY, intense competition in the MS market, unexpected hurdles or difficulties in launching PLEGRIDY, difficulties obtaining or changes in the availability of reimbursement for PLEGRIDY, problems with our manufacturing processes for PLEGRIDY, the occurrence of adverse safety events, and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

References

¹ Calabresi PA et al. Peginterferon Beta-1a Provides Improvements in Clinical and Radiological Disease Activity in Relapsing-Remitting Multiple Sclerosis: Year 1 Findings from the Phase 3 ADVANCE. Poster presented at 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, 2013.

² Bailon P and Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6: 1-16, 2009.

³ Reuss R. PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update. Biologics: Targets and Therapy 7: 131-139, 2013. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/pdf/btt-7-131.pdf. Accessed March 2014.

⁴ Multiple Sclerosis International Federation, Atlas of MS 2013. Epidemiology of MS. Page 8. Date Accessed: Mar. 17, 2014. http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1

⁵ Multiple Sclerosis International Federation. Atlas of MS 2013. Epidemiology of MS. Date Accessed: Mar. 17, 2014. http://www.atlasofms.org/query.aspx

⁶ NMSS. Relapsing-Remitting MS. Date accessed: Mar. 17, 2014. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS

(INO) HPV Immunotherapy Nails Primary Efficacy Endpoint in Cervical Dysplasia

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses

PLYMOUTH MEETING, Pa., July 23, 2014  — Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment with VGX-3100, Inovio’s HPV16/18-specific immunotherapy, resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study’s primary endpoint. In addition, the trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.

“This is a significant step toward providing women and their physicians a non-surgical approach to the treatment of precancerous lesions by stimulating their immune system to eliminate high risk HPV infection and induce regression of a cervical intraepithelial neoplastic process,” said Mark Bagarazzi, MD, Chief Medical Officer, Inovio Pharmaceuticals. “This proof of concept trial will guide the advancement of VGX-3100 for precancerous dysplasias as well as HPV-associated cervical, head and neck, and anogenital cancers.”

Treatment was randomized 3:1 between the VGX-3100 and placebo groups, and was stratified by age and severity of CIN. The primary endpoint, histologic regression, was evaluated 36 weeks after the first treatment. In the per protocol analysis, CIN2/3 resolved to CIN1 or no disease in 53 of 107 (49.5%) women treated with VGX-3100 compared to 11 of 36 (30.6%) who received placebo. This difference was statistically significant (p<0.025).

Virological clearance of HPV 16 or 18 from the cervix in conjunction with histopathological regression of cervical dysplasia to CIN1 or no disease, a secondary endpoint of the trial, was observed in 43 of 107 (40.2%) VGX-3100 recipients compared to 5 of 35 (14.3%) placebo recipients (p<0.025).

As in the phase I study, VGX-3100 elicited robust HPV-specific T cell responses in the majority of treated subjects. A comprehensive analysis of T cell responses is ongoing.

The treatment was generally well-tolerated, with only administration site redness occurring significantly more frequently in the VGX-3100 group compared to the placebo group in the 7- and 28-day periods following treatment.

“Beyond the direct clinical implications of this phase II study, these results are a breakthrough for the field of immunotherapies. This efficacy and T cell data provide evidence that our SynCon^® immunotherapy technology can activate the immune system to fight chronic infections, pre-cancers — and ultimately, cancers,” said Dr. J. Joseph Kim, Inovio’s President and CEO. “These results significantly de-risk our product and business development strategy for VGX-3100 and our broad pipeline of SynCon^® active immune therapy and vaccine products.

“We thank the women who participated and the clinical investigators who provided patient care and made this trial possible.”

Topline results will be presented at the 2014 International Society of DNA Vaccines Conference in San Diego, on July 23, 2014. Detailed study findings will be submitted for publication in a peer-reviewed scientific journal.

About VGX-3100

Inovio’s VGX-3100 is an immunotherapy containing two DNA plasmids targeting the E6 and E7 oncogenes of HPV types 16 and 18. The treatment is administered to patients by injection into muscle (typically in the arm), followed by electroporation using Inovio’s CELLECTRA^® device. VGX-3100 has been shown to induce a robust immune response against the E6 and E7 oncogenes associated with HPV types 16 and 18. These oncogenes are responsible for transforming HPV-infected cells into pre-cancerous and cancerous cells. Apart from this cervical dysplasia study, Inovio is also conducting studies using this immunotherapy against cervical as well as head and neck cancers caused by these HPV types.

About HPV-003 (ClinicalTrials.gov: NCT01304524; EudraCT: 2012-001334-33)

This phase II trial is a randomized, placebo-controlled, double-blind study of women with CIN2 or CIN3 who were randomized 3:1 to the active and placebo groups. Women in the active group received three 6 mg doses of VGX-3100 in a 1 mL intramuscular injection followed by electroporation with Inovio’s CELLECTRA® device at weeks 0, 4, and 12. Cervical tissue was examined before starting blinded treatment and 9 months later.

Cornelia Trimble, MD, Associate Professor of Gynecology and Obstetrics, Oncology, and Pathology, Johns Hopkins School of Medicine, is the principal investigator for the study.

About HPV and Cervical Dysplasia

Human papillomavirus (HPV) is the most common sexually transmitted disease. At any given time, approximately 11% percent of the world population is infected with HPV. Roughly 90% of HPV infections are cleared by naturally occurring immune responses within two years.

Persistent HPV infection can lead to dysplasia, or premalignant changes, in cervical cells. HPV types 16 and 18 cause 70% of cervical dysplasia and cervical cancer cases. Each year in the United States, 1.4 million women are diagnosed with CIN1 and 300,000-400,000 women are diagnosed with CIN 2/3. All cervical cancers arise from untreated CIN2/3.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon^® active immune therapy and vaccine products, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended March 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(RCON) Strengthens Communications Team

BEIJING, July 22, 2014 —Recon Technology (NASDAQ: RCON), a leading independent oilfield services provider operating primarily in China, today announced that it has strengthened its communication team with the addition of two bilingual staffers with American educational backgrounds who will report to Ms. Jia Liu, Recon’s CFO. The Company also has brought on board a new U.S. IR agency.

Ms. Tianyu (Ivy) Xia, who has joined the Company as Investor Relations Manager, recently earned an M.S. in Investor Relations from Fordham University in New York, and holds a B.S. in Accounting from the John Cook School of Business at Saint Louis University, and is a member in the U.S. of the National Investor Relations Institute (NIRI). Additionally, Ms. Lulu Chen, who has a background in operations management, and earned a Bachelor’s Degree at the University of North Texas, has joined Recon as Board Secretary.

Recently, the Company also appointed DGI Investor Relations in New York as its IR agency. The firm is led by Mr. Ken Donenfeld, who has assisted large and small companies throughout Europe, Asia and North America for more than 30 years.

Aiming to Reach Out to Investors

Mr. Shenping Yin, Chairman of the Company, commented, “We believe Recon has an excellent ‘story’ for investors who share our belief in the outstanding long term growth potential of China’s oil and gas industry where we are continuing to build our leadership position. Entering the new fiscal year with our expanded communications team and an experienced New York-based consultant, we believe the timing is right to reach out to investors to create a better understanding of our Company.”

About Recon

Recon Technology, Ltd. is China’s first independent oil and gas field service company listed on NASDAQ (RCON). Recon has achieved rapid growth supplying China’s largest oil and gas exploration companies, including Sinopec and China National Petroleum Corporation, with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measures closely working with leading global partners such as Baker Hughes. The solutions Recon provides are aimed at increasing gas and petroleum extraction levels, reducing impurities and lowering production costs. For additional information, please visit www.recon.cn.

Safe Harbor

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission.

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contacts:

Liu Jia
Recon Technology, Ltd.
+86 (10) 84945799
info@recon.cn

U.S. Investors
DGI Investor Relations
Ken Donenfeld
kdonenfeld@dgiir.com
1-212-425-5700

(GALE) Exclusive Licensing Agreement With MonoSol Rx

Will Use PharmFilm(R) Technology for Treatment of Chemotherapy, Radiation and Post Operative-Induced Nausea and Vomiting

WARREN, N.J., July 22, 2014  — MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced that it has licensed Zuplenz^® (ondansetron) to Galena Biopharma, a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Zuplenz is an oral soluble film (OSF) for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting.

The licensing agreement includes an undisclosed upfront payment from Galena, as well as double digit royalty payments from sales of Zuplenz. Zuplenz is the first oral soluble lingual film product approved by the U.S. Food and Drug Administration (FDA) as a prescription medication, based on MonoSol Rx’s proprietary PharmFilm^® technology.

Keith J. Kendall, Co-President and Chief Operating Officer of MonoSol Rx, remarked, “Partnering with Galena Biopharma to provide Zuplenz to patients in need further reinforces MonoSol Rx’s position as a leader in the oral soluble film pharmaceutical market. Through this partnership, we hope to empower supportive care providers with a more comfortable, easier-to-use formulation of ondansetron that addresses a significant unmet medical need, particularly among cancer patients. With the increased availability of Zuplenz, clinicians will be able to improve the level of care they provide by utilizing our innovative drug delivery technology to eliminate swallowing issues and discomfort associated with chemotherapy, radiotherapy, and surgery.”

“We are pleased to be working with MonoSol Rx to offer Zuplenz to patients in need,” said Mark J. Ahn, Ph.D., President and Chief Executive Officer of Galena Biopharma. “MonoSol Rx’s oral film delivery technology represents a substantive advancement in terms of ease of use and compliance for supportive care patients, where difficulty swallowing can be a major issue. Providing patients with an alternative solution for nausea and vomiting has long been a concept that oncologists and the general surgeon and oncology nurse communities have sought, and that we are eager to deploy.”

Zuplenz is a unique formulation of ondansetron using MonoSol Rx’s proprietary PharmFilm^® technology, co-developed with partner APR Applied Pharma Research s.a. of Switzerland. It is based on a novel and proprietary oral drug delivery technology platform and consists of a polymeric OSF containing ondansetron. Once placed in the mouth, it dissolves in a few seconds, allowing the medication to be absorbed and delivered without water.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company’s leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals – Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence. For press releases and other company information, visit www.monosolrx.com.

* PharmFilm is a registered trademark of MonoSol Rx.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information, visit www.galenabiopharma.com.

About APR Applied Pharma Research

APR is an independent, international and integrated Healthcare Company headquartered in Switzerland, which focuses on three major areas: Delivering, Funding and Supporting Innovation in Healthcare. In particular, APR develops and licenses innovative, value added and patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early stage innovative projects and provides a balanced mix of equity funding and/or financing together with APR’s development, scientific, technical, marketing, licensing and management skills and know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basis added value, consultancy and R&D services under contract using a General Contractor approach. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 100 countries worldwide with international sales on a worldwide basis.

CONTACT: MonoSol Rx:
         Sanford Plachter
         Marketing Manager
         (732) 564-5000

         The Ruth Group for MonoSol Rx
         Aaron Estrada (media)
         (646) 536-7028
         aestrada@theruthgroup.com

         Lee Roth (investors)
         (646) 536-7012
         lroth@theruthgroup.com

(MOBL) Launches Fully Automated Cloud Solution for Enterprise Mobility Management in Japan

MobileIron Cloud Data Center Located in Tokyo

TOKYO, July 22, 2014  — MobileIron (NASDAQ: MOBL), a leader in enterprise mobility management (EMM), today announced the Japanese availability of MobileIron Cloud, the next-generation cloud solution for enterprise mobility management (EMM). Fully automated and localized for Japan, MobileIron Cloud provides users with seamless access to the business apps and content they need on their mobile devices while ensuring that IT can properly secure corporate data.

“It’s been exciting to watch our Japanese customers realize the business advantages of enabling their employees with mobile apps and content,” said Bob Tinker, CEO of MobileIron. “With MobileIron Cloud, they can make the transition from basic mobile device management to enterprise mobility management with unprecedented speed and ease of use.”

Gartner reports that “one in every four Japanese CIOs has made significant investment in public cloud. Even more than in the global results, the dominant reason in Japan is agility, not cost”. [1] MobileIron Cloud combines the agility of the cloud with the enterprise-grade security of MobileIron’s leading EMM platform. MobileIron’s layered security model allows organizations to protect sensitive corporate data without impacting the user experience on the mobile device. Layered security includes the ability to secure enterprise email, apps and content without monitoring or modifying personal data; use certificates to establish and authenticate identity; provide closed-loop automation to automatically trigger notifications, quarantine and other access policies when devices fall out of compliance; and provide employees with self-service tools for registration, checking compliance and remediation.

MobileIron Cloud benefits for IT:

• Deploy in minutes
• Automate mobile security
• Manage, secure and track data across thousands of mobile apps, files and devices
• Day zero support for new handsets of supported manufacturers
• Keep pace with mobile technology development
• Scale to support a global mobile enterprise with millions of devices
• Provide uninterrupted mobile management through local high availability and global disaster recovery

MobileIron Cloud benefits for employees:

• Use work apps and content with the same consumer-grade experience they get with personal apps and files
• Reduce help desk calls and eliminate the need for training with an intuitive user interface
• Manage devices through a self-service portal to lock, unlock, wipe or retire personal devices

“MobileIron Cloud combines a fantastic user experience with the enterprise-grade security customers expect from MobileIron,” said Mikio Yanashita, Vice President of Sales Asia Pacific Region at MobileIron. “Japanese CIOs are looking for agility and the cloud is the answer. As part of our commitment to the Japanese market, we are delivering a fully automated product so that Japanese organizations can realize immediate efficiencies of both enterprise mobility and the cloud.”

About MobileIron
MobileIron provides the foundation for companies around the world to transform into Mobile First organizations. For more information, please visit www.mobileiron.com.

(ATAI) Joint Venture With New Oriental Education & Technology Group

Two Companies to Leverage Respective Strengths, ATA’s Technology and Student Resources and New Oriental’s Expansive Education Network and Capabilities

(GRH) Announces Intent To Form Master Limited Partnership

GreenHunter Resources, Inc. (NYSE MKT: GRH) (NYSE MKT: GRH.PRC), a diversified water resource, waste management, environmental services, and hydrocarbon marketing company specializing in the unconventional oil and natural gas shale resource plays, announced today that it has filed with the Internal Revenue Service a request for a ruling that income derived by a newly formed Limited Partnership (“MLP”) for the handling of fluid storage, treatment and disposal services, frac tank rental, water monitoring services, and environmental remediation services that constitute a part of the exploration, developmental, mining, processing, refining, and transportation of natural resources will in fact constitute “Qualified Income” under certain sections of the Internal Revenue Code of 1986, as amended.

Due to substantial growth experienced over the last couple of years that has caused GreenHunter Resources to quickly become the leader in Total Water Management Solutions™ in the Appalachian region, as well as the anticipated future growth from the various projects planned by the Company over the next three years, management and the board have determined that utilizing a MLP structure will be the most cost efficient way to fund our future capital needs.

About GreenHunter Resources, Inc.

GreenHunter Resources, Inc., through its wholly-owned subsidiaries, GreenHunter Water, LLC, GreenHunter Environmental Solutions, LLC, and GreenHunter Hydrocarbons, LLC, provides Total Water Management Solutions™/Oilfield Fluid Management Solutions™ in the oilfield and its shale plays of the Appalachian Basin. GreenHunter Water continues to expand its services package by increasing down-hole injection capacity with Class II salt water disposal wells and facilities, with the launch of next-generation modular above-ground frac water storage tanks (MAG Tank™), and with advanced water hauling – including a growing fleet of DOT rated 407 trucks, for hauling condensates and water with the presence of condensates. GreenHunter Water has also spearheaded the movement to barge brine water, as barging is the safest and most cost-effective mode of transport.

GreenHunter Environmental Solutions, LLC offers onsite environmental solutions at the well pad and facilities, with a service package that includes tank and rig cleaning, liquid and solid waste removal/remediation, solidification, and spill response. An understanding that an interconnected suite of services is key to E&P waste stream management shapes GreenHunter Resources’ comprehensive end-to-end approach to services.

GreenHunter Hydrocarbons, LLC offers transportation of hydrocarbons (oil, condensate, and NGLs) and will soon offer storage, processing, and marketing of hydrocarbons (oil, condensate, and NGLs) in the Appalachian region, leveraging off of our existing asset base and infrastructure, which includes up to six different barge terminal locations, presently owned or leased by GreenHunter Resources.

For a visual animation of the Class II Salt Water Disposal well development and completion technique that is being utilized in GreenHunter Water’s Appalachia SWD program, navigate to the video by clicking on “Salt Water Disposal Animation” button on the Operations tab at GreenHunterEnergy.com or click here.

Additional information about GreenHunter Water may be found at www.GreenHunterWater.com

Forward-Looking Statements

Any statements in this press release about future expectations and prospects for GreenHunter Resources and its business and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the substantial capital expenditures required to fund its operations, the ability of the Company to implement its business plan, government regulation and competition. GreenHunter Resources undertakes no obligation to update these forward-looking statements in the future.

(FCEL) German Government Support for Clean and Efficient Fuel Cells

FuelCell Energy Solutions, GmbH and Joint-Venture Partner Fraunhofer IKTS to Further Enhance Performance of Stationary Fuel Cell Power Plants

DANBURY, Conn., July 22, 2014  — FuelCell Energy, Inc. (Nasdaq:FCEL) a global leader in the design, manufacture, operation and service of ultra-clean, efficient and reliable fuel cell power plants, today announced that its affiliate FuelCell Energy Solutions, GmbH (FCES) has received nearly €5 million in awards by Germany’s Federal Ministry for Economic Affairs and Energy to support a three year research and development project between FCES and joint venture partner Fraunhofer IKTS. The project targets further enhancements to the Direct FuelCell® (DFC®) technology by increasing power density and operating life of the fuel cells, leading to lower costs. The research is being performed in Germany by FCES at an existing facility in Ottobrunn and by Fraunhofer IKTS at a facility located in Dresden.

“Fraunhofer IKTS continues to undertake fuel cell research in recognition that the attributes of high efficiency, virtual lack of emissions, low carbon output, and ability to easily site fuel cell plants in populated areas can help address the power generation challenges facing Germany and many other European countries,” said Prof. Dr. Alexander Michaelis, Director of Fraunhofer IKTS. “The awards from the Federal Ministry for Economic Affairs and Energy will help expand Germany’s existing fuel cell knowledge and assist in advancing the technology towards greater adoption that should support economic development in Germany.”

“With the support of various government organizations, strategic partners and private industry, product, performance and system enhancements continue on our proprietary fuel cell technology and are now being performed on three continents; validating the global interest in our power and hydrogen generation solutions that enhance the resiliency of power distribution in an ultra-clean and affordable manner,” said Chip Bottone, President and Chief Executive Officer of FuelCell Energy, Inc. and Managing Director of FuelCell Energy Solutions GmbH. “We utilize a common global technology platform so enhancements developed under these awards can support global markets further strengthening the attractiveness of our product offerings.”

The research and development program aims to enhance the DFC^® fuel cell performance by increasing the power output of the fuel cell stack, making the fuel cell power plants even more affordable based on increased power output from the fuel cells and extended operating life for the fuel cell stack. With growing adoption supported by this research program, enhancement of the fuel cell manufacturing in Germany is expected to follow, leading to job creation from manufacturing and the associated supply chain multiplier effect.

Fuel cells electrochemically convert a fuel source into electricity and heat in a highly efficient process that emits virtually no pollutants due to the absence of combustion. Direct FuelCell^® (DFC^®) stationary power plants utilize carbonate fuel cell technology and provide continuous baseload power located where the power is used, including both on-site applications and electric grid support. The combination of near-zero pollutants, modest land-use needs, and quiet operating nature of these power plants facilitates locating the power plants in urban locations. The power plants are fuel flexible, capable of operating on natural gas, on-site renewable biogas, or directed biogas.

FCES, with its German manufacturing base, is the sales, manufacturing and service business for the European Served Area for FuelCell Energy, Inc. FCES is a joint venture between Fraunhofer IKTS and FuelCell Energy, Inc.

Founded in 1949, Fraunhofer is Europe’s largest application-oriented research organization with an annual research budget of €1.8 billion (approximately $2.3 billion) and more than 18,000 staff, primarily scientists and engineers. Fraunhofer has research centers and representative offices in Europe, USA, Asia and the Middle East, and more than 80 research units, including 60 Fraunhofer Institutes, at different locations in Germany. The Fraunhofer IKTS with its staff of 620 highly educated engineers, scientists and technicians is a world leading institute in the field of advanced ceramics for high-tech applications. The primary markets for Fraunhofer IKTS include energy and environmental technology with a focus on fuel cell development and commercialization. Website: www.ikts.fraunhofer.de/en.html.

About FuelCell Energy

Direct FuelCell® power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide. With more than 300 megawatts of power generation capacity installed or in backlog, FuelCell Energy is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world. The Company’s power plants have generated more than 1.7 billion kilowatt hours of ultra-clean power using a variety of fuels including renewable biogas from wastewater treatment and food processing, as well as clean natural gas. For more information, please visit www.fuelcellenergy.com

See us on YouTube

Direct FuelCell, DFC, DFC/T, DFC-H2 and FuelCell Energy, Inc. are all registered trademarks of FuelCell Energy, Inc. DFC-ERG is a registered trademark jointly owned by Enbridge, Inc. and FuelCell Energy, Inc.

CONTACT: FuelCell Energy, Inc.
         Kurt Goddard
         Vice President Investor Relations
         203-830-7494
         ir@fce.com

         Fraunhofer IKTS
         Katrin Schwarz
         +49 2553 7720
         katrin.schwarz@ikts.fraunhofer.de

(CGIX) Acquisition of Gentris Corporation

• Acquisition Adds Contracts With Five of the Top Biopharma Companies Globally
• Increases Overall Biopharma Contract Backlog to Over $18 Million
• Uniquely Positions CGI to Provide Genomic Testing Globally Including China, One of Fastest Growing Countries For Both Clinical Trials and Cancer Testing

RUTHERFORD, N.J., July 21, 2014 — Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics focused on developing genomic-based oncology tests and services, today announced the signing of a definitive agreement to acquire privately held Gentris Corporation, a global provider of clinical pharmacogenomics solutions, next-generation sequencing, and biomarker testing.

CGI expects the acquisition to add approximately $5 to $6 million in annual sales, and add substantially to it biopharma revenue backlog and capabilities. The company will now be positioned to provide global services for genomic and biomarker testing for biotech and pharmaceutical companies by leveraging both it’s unique tests and comprehensive oncology services.

Gentris provides genomic testing and pharmacogenomics services to half of the top ten biopharma companies globally and has participated and performed genomic analysis for over 1,000 clinical trials. The company has operations in Raleigh (Research Triangle Park), North Carolina and Shanghai, China in state-of-the-art GLP, CLIA and FDA-compliant facilities.

Gentris’ expertise in pharmacogenomics, the study of the role of an individual’s genetics in drug response, enables its clients to quickly obtain and translate quality genomic biomarker results into safer, more effective medicines that improve and personalize the standard of care for patients globally. Gentris also adds CAP accredited biorepository and tissue management services for CGI’s growing global client base through an additional 28,000 square feet of laboratory space.

Panna Sharma, CEO of Cancer Genetics, stated: “The acquisition of Gentris will serve as a strong foundation for the expansion of our programs into the clinical and hospital setting globally. We now have fully staffed laboratories in the U.S., India and China, which gives us a uniquely competitive platform to develop, commercialize, and deliver genomic and biomarker based oncology diagnostics to our clients. Importantly, this acquisition provides a clear pathway and high growth opportunity to sell our genomic based diagnostic tests to some of the largest pharma companies in the world with additional capabilities such as germline DNA testing and drug response optimization and monitoring.”

Mr. Sharma also added: “The fact that large biopharma companies are continuing to invest heavily in China and that cancer is now the single largest cause of death in China, makes it important that CGI expand its operations and capabilities in this market. Gentris’ presence in China provides us the platform to do so.” According to Thomson-Reuters clinical intelligence service, Cortellus, 550 to 600 clinical trials are initiated in China each year with nearly forty percent focused on oncology.

With the acquisition of Gentris, and the previously announced BioServe India acquisition, Cancer Genetics will have approximately 60,000 square feet of state-of-the-art lab space and will have established itself as a unique global provider for the development and delivery of targeted, personalized oncology diagnostics.

About Cancer Genetics

Cancer Genetics, Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Its tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. It also offers a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Its state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. It has established strong research collaborations with major cancer centers including Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that we will not reach agreement on definitive acquisition agreements with Gentris, or that the Gentris and/or BioServe transactions will not close or, if either or both closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations
         Andrew McDonald
         LifeSci Advisors, LLC
         646-597-6987

         Public Relations
         John Cunningham
         RedChip Companies, Inc.
         800-733-2447 x 105

(BIOL) to Raise $12 Million from Institutional and Individual Investors in Private Placement

BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, announced today that Jack W. Schuler, Oracle Partners, L.P. and other Oracle funds, Birchview Capital and certain BIOLASE directors and officers have agreed to purchase $12 million of unregistered shares of BIOLASE common stock in a private placement transaction. Under the terms of the private placement, BIOLASE has agreed to sell an aggregate of 6,250,000 shares of its common stock at the price of $1.92 per share. In connection with the transaction, BIOLASE agreed to use commercially reasonable efforts to file within 30 days of the closing a registration statement with the Securities and Exchange Commission to register the resale of the shares issued at the closing.

The private placement is expected to close on or about July 22, 2014, subject to customary closing conditions. The proceeds will be used to repay all outstanding indebtedness under BIOLASE’s loan agreement with Comerica Bank and for working capital and general corporate purposes.

Northland Securities, Inc. acted as exclusive placement agent in connection with the offering.

Paul N. Clark, Chairman of the Board of Directors of BIOLASE, said, “We are very pleased to have completed this important private placement financing at market with a number of veteran institutional and individual biotechnology investors, and we expect the proceeds raised to fuel the Company’s growth and innovation efforts.”

Jeffrey M. Nugent, Acting Chief Executive Officer and director of BIOLASE, said, “This investment will help us accomplish our goal to expand BIOLASE’s global leadership position in superior laser technology across a select range of healthcare needs, while primarily focusing on improving the practice of dentistry.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.

About BIOLASE, Inc.

BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2-D and 3-D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3-D printers — products that are focused on technologies that advance the practice of dentistry and medicine. BIOLASE’s proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices aimed to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 25,000 laser systems. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE^® and WaterLase^® are registered trademarks of BIOLASE, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provided by the Securities Reform Act of 1995. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “aims,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on BIOLASE’s current expectations and are subject to risks, uncertainties and other factors that may cause BIOLASE’s actual results to differ materially from the statements contained in this press release, including those described in Item 1A of BIOLASE’s annual report on Form 10-K for the fiscal year ended December 31, 2013, filed with the Securities and Exchange Commission. The forward-looking statements included in this release are made as of the issuance of this release, and except as required by law, BIOLASE undertakes no obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the issuance of this release.

(STLD) To Acquire Severstal Columbus Acquisition To Accelerate Future Growth

– $1.625 billion acquisition of Severstal Columbus to be funded with available cash and debt – Significantly expands Steel Dynamics’ operating base with 3.4 million tons of hot roll steel production capacity through acquisition of one of the most modern mini-mills in North America – Broadens Steel Dynamics’ product portfolio by adding capabilities serving high margin customers in the OCTG and automotive sectors – Allows Steel Dynamics to build a geographic market position in the Southern U.S. with exposure to growing southern and Mexican industrial manufacturing hubs – Strong fit with an impressive safety-oriented, non-union operating culture

FORT WAYNE, Ind., July 21, 2014 — Steel Dynamics, Inc. (NASDAQ/GS: STLD) today announced that it has entered into a definitive agreement to acquire 100% of Severstal Columbus, LLC (“Columbus”) from OAO Severstal.  Located in northeast Mississippi, Columbus is one of the newest and most technologically advanced mini-mills in North America.  Steel Dynamics will purchase Columbus for $1.625 billion in cash, subject to customary transaction purchase price adjustments.

The acquisition expands Steel Dynamics’ annual steel shipping capacity to 11.0 million tons, representing an approximate 40 percent increase.  The additional exposure to the high-growth OCTG and automotive segments complements Steel Dynamics’ market offerings.  Commissioned in 2007, Columbus is one of the only North American flat roll mills to have 76 inch wide hot roll, 74 inch wide cold roll, and 72 inch wide galvanized sheet capabilities.  These and other production capabilities will broaden Steel Dynamics’ product portfolio with regard to width, gauge and strength and enhance the Company’s position as a leading North American steel producer.

“The acquisition of Columbus represents a significant step in the continuation of our growth strategy,” stated Chief Executive Officer, Mark Millett.  “It leverages our core strengths, and at the same time fulfills our initiatives to further increase value-added product and market diversification.  We enthusiastically look forward to welcoming the Columbus employees and customers into the Steel Dynamics family, and working with them to drive future growth and success.”

“We have been positioning our balance sheet and organizational structure for growth such as this,” continued Millett, “and we believe this acquisition will result in a prudent capital structure that will allow us to again return to our preferred net debt leverage of less than three times trailing EBITDA within a reasonable timeframe.  The expected earnings accretion and increased scale make this transaction a meaningful strategic opportunity for our shareholders and all of our employees.”

The transaction is expected to be immediately accretive to earnings and cash flow per share, and to generate approximately $30 million in pretax earnings synergies per annum.

Overview of Columbus

Columbus is one of North America’s newest mini-mills with an estimated annual hot roll production capacity of 3.4 million tons and 645 employees.  Columbus produces a broad range of high-quality hot-rolled, cold-rolled and galvanized sheet products for customers primarily in the distributor, construction, automotive and pipe and tube markets.  Columbus is strategically located in Mississippi to serve the high-growth markets in the Southern U.S. and Mexico, providing geographic diversification and growth opportunities for Steel Dynamics.

Initial construction for Columbus commenced in October 2005 with plant commissioning in August 2007 and first coil shipment in September 2007.  Between August 2007 and November 2011, a second electric arc furnace, ladle metallurgy furnace, caster, tunnel furnace, hot dip galvanizing line and a heavy gauge push pull pickle line were added.

Transaction Details

The transaction has been approved by the boards of directors of each of Steel Dynamics and OAO Severstal.  The transaction is subject to customary conditions and receipt of regulatory approvals.  Steel Dynamics expects to obtain all necessary regulatory approvals and complete the transaction prior to year end.

The purchase price will be paid in cash and is subject to customary working capital adjustments dependent upon the exact date of closing.  The transaction is supported by a fully committed $1.0 billion bridge facility provided by Goldman Sachs.  Steel Dynamics expects that the permanent financing for the transaction, which will include a combination of available cash on hand and new debt, will allow it to maintain its current credit rating.

Goldman Sachs acted as exclusive financial advisor to Steel Dynamics and Barrett & McNagny LLP acted as legal advisor.

Investor Conference Call and Webcast

On Monday, July 21, 2014, at 9:30 a.m. Eastern Time, Steel Dynamics will host a conference call with investors and analysts to discuss the Columbus transaction.  We invite you to listen to the live audiocast of the conference call accessible from our website (http://www.steeldynamics.com), or via telephone (the conference call number may also be obtained on our website).   An investor presentation will be posted on the webiste for reference during the conference call.  A replay of the discussion will be available on our website until 11:59 p.m. Eastern Time on July 28, 2014.  A podcast/MP3 file of the event will also be available and can be downloaded from our website.

About Steel Dynamics, Inc.

Steel Dynamics, Inc. is one of the largest domestic steel producers and metals recyclers in the United States based on current estimated annual steelmaking and metals recycling capability, with annual sales of $7.4 billion in 2013, over 6,800 employees, and manufacturing facilities primarily located throughout the United States (including five existing steel mills, six steel processing facilities, two iron production facilities, over 90 metals recycling locations and six steel fabrication plants).

Forward-Looking Statement

This press release contains some predictive statements about future events, including statements related to conditions in the steel and metallic scrap markets, Steel Dynamics’ production capacities, shipments, revenues, material costs, future profitability and earnings, and the operation of new or existing facilities. These statements are intended to be made as “forward-looking,” subject to many risks and uncertainties, within the safe harbor protections of the Private Securities Litigation Reform Act of 1995. These statements speak only as of this date and are based upon information and assumptions, which we consider reasonable as of this date, concerning our businesses and the environments in which they operate. Such predictive statements are not guarantees of future performance, and we undertake no duty to update or revise any such statements. Some factors that could cause such forward-looking statements to turn out differently than anticipated include: (1) the effects of uncertain economic conditions; (2) cyclical and changing industrial demand; (3) changes in conditions in any of the steel or scrap-consuming sectors of the economy which affect demand for our products, including the strength of the non-residential and residential construction, automotive, appliance, pipe and tube, and other steel-consuming industries; (4) fluctuations in the cost of key raw materials (including steel scrap, iron units, and energy costs) and our ability to pass-on any cost increases; (5) the impact of domestic and foreign import price competition; (6) unanticipated difficulties in integrating or starting up new or acquired businesses; (7) risks and uncertainties involving product and/or technology development; and (8) occurrences of unexpected plant outages or equipment failures.

More specifically, we refer you to SDI’s more detailed explanation of these and other factors and risks that may cause such predictive statements to turn out differently, as set forth in our most recent Annual Report on Form 10-K, in our quarterly reports on Form 10-Q or in other reports which we from time to time file with the Securities and Exchange Commission. These are available publicly on the SEC Web site, www.sec.gov, and on the Steel Dynamics Web site, www.steeldynamics.com.

(ITI) Announces Receipt of Notice of Noncompliance with NYSE MKT Listing Standards

Iteris, Inc. (NYSE MKT: ITI), a leader in providing intelligent traffic management and weather information solutions, announced that, on July 17, 2014, the Company received a letter from the NYSE MKT LLC (the “Exchange”) indicating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange’s Company Guide (the “Company Guide”) due to the Company’s inability to file its Annual Report on Form 10-K for the year ended March 31, 2014 (the “Form 10-K”) with the SEC by the requisite deadline. In the letter issued to the Company, the Exchange advised the Company that, in order to maintain its listing of securities on the Exchange, the Company must submit a plan to the Exchange by July 31, 2014, detailing the action the Company plans to take to bring it into compliance with the continued listing standards of the Company Guide by October 15, 2014. The Company has submitted to the Exchange the Company’s plan on July 21, 2014. If the Company’s plan is not accepted by the Exchange, or if the Company is not in compliance with the Exchange’s continued listing standards within the timeframe provided or does not make progress consistent with its plan by October 15, 2014, then the Exchange will initiate delisting proceedings as it deems appropriate. As previously announced, the Company plans to file its Form 10-K within the next three to six weeks.

About Iteris, Inc.

Iteris, Inc. (NYSE MKT: ITI) is a leader in providing intelligent information solutions to the traffic management market. The company is focused on the development and application of advanced technologies and software-based information systems that reduce traffic congestion, provide measurement, management, and predictive traffic and weather analytics, and improve the safety of surface transportation systems. By combining its unique IP, products, decades of expertise in traffic management, hyper-local weather solutions and information technologies, Iteris offers a broad range of Intelligent Transportation System (ITS) solutions to customers worldwide. The firm is headquartered in Santa Ana, California, with offices nationwide and in the Middle East. For more information, please call 1-888-329-4483 or visit us at www.iteris.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This release may contain forward-looking statements, which speak only as of the date hereof and are based upon our current expectations and the information available to us at this time. Words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “can,” and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about the timing of the Company’s filing of its Form 10-K. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict, and actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

Important factors that may cause such a difference include, but are not limited to, the ability of our auditors to complete the audit of our financial statements on a timely basis; management’s ability to adequately respond to any follow-up inquiries of our auditor; or the completion of any additional procedures and/or testing required by our auditors. Further information on Iteris, Inc., including additional risk factors that may affect our forward-looking statements, is contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, and our other SEC filings that are available through the SEC’s website (www.sec.gov).

(CPAH) Awarded Patent for Mobile Network Based Authentication

Patent enables operators to offer Over the Top (OTT) communications with trusted mobile based user authentication, simplifying mobile services over non-mobile devices

CounterPath Corporation
Kasia Finkelstein
(604) 628-9378
kfinkelstein@counterpath.com

(CLWT) Reports Ballast Water Treatment Systems Update

HONG KONG, July 21, 2014  — Euro Tech Holdings Company Limited (Nasdaq: CLWT) today reported that the company has recently obtained type approval certificate from China’s Classification Society (CCS) for its 300 Cubic Meters per hour BWTS.

The company is planning to develop a larger size of BWTS of 750 Cubic Meters per hour to meet different requirements of its potential customers, while looking for qualified personnel and distribution channels to market and sell its existing BWTS. The company may seek strategic partners or external investors for further expansion of its BWTS business.

About BWTS

BWTS is an imminent requirement by The International Maritime Organization (“IMO”) to prevent the biological unbalance caused by the estimated 12 billion tons of ballast water transported across the seas by ocean-going vessels when their ballast water tanks are emptied or refilled. In 2012, ballast water discharge standard became a law in the US. Any vessel constructed in December 2013 or later will need to comply when entering US waters, and existing vessels will follow shortly after. The market potential for retrofits and new installations of BWTS in these old and new ocean-going vessels is enormous.

Certain statements in this news release regarding the Company’s expectations, estimates, present view of circumstances or events, and statements containing words such as estimates, anticipates, intends, or expects, or words of similar import, constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements indicate uncertainty and the Company can give no assurance with regard to actual outcomes. Specific risk factors may include, without limitation, having the Company’s offices and operations situated in Hong Kong and China, doing business in China, competing with Chinese manufactured products, competing with the Company’s own suppliers, dependence on vendors, and lack of long term written agreements with suppliers and customers, development of new products, entering new markets, possible downturns in business conditions, increased competition, loss of significant customers, availability of qualified personnel, negotiating definitive agreements, new marketing efforts and the timely development of resources. See the “Risk Factor” discussions in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for its fiscal year ended December 31, 2013.

(NETE) SeeThruEquity Initiates Research Coverage, Target Price of $3.47

New York, NY / July 21, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Net Element, Inc. (NASDAQ: NETE).

“We are excited about NETE’s growth potential over the next 2-3 years. As merchants and consumers continue to shift to a cashless environment, we see NETE as an emerging leader in mobile payments, value-added services and technologies. We look forward to following the company and are initiating coverage with a price target of $3.27 per share.”

Additional investment highlights are as follows:

– Repositions business activities. As part of a renewed strategy to reposition business activities and focus on mobile payments and transactional processing solutions, NETE completed a number of acquisitions and dispositions in 2013. The company divested its non-core online media/entertainment business assets in the third quarter of 2013. NETE entered the payment processing and financial technology businesses through the acquisitions of Unified Payments in April 2013 and Aptito in June 2013. We believe the repositioning has made NETE a strong financial technology-driven service company capable of providing end-to-end payment solutions to enable commerce globally. The acquisition of Unified Payments was a significant milestone, which drove the company revenues more than ten-fold in 2013 to $19 million.

– Tremendous market opportunity. The total addressable market for transaction processing in the U.S. is large and growing, offering enormous growth potential for NETE. According to the Nilson Report, market for all card type transactions in the U.S is expected to grow at 9.8% annually to $6.0 trillion by 2017. Global market for mobile m-payments and e-commerce is estimated at $796 billion and $1.8 trillion in 2014, according to Capgemini World Payments Report 2013. We believe NETE is well positioned to capture an increasing slice of both transaction processing market and mobile payments in the U.S. and in emerging markets through renewed sales and marketing approaches complemented by its next generation proprietary technologies and value added services including TOT Platform, Payment Browser and Aptito.

– Diverse and recurring revenue streams. NETE’s broad portfolio of payment processing and financial technology solutions leverage the growth in payments to deliver a diverse mix of recurring revenues with low customer concentration. The company’s credit card payment processing services in the U.S. serve SME merchants across diverse industries with each SME typically processing on average $10,000 a month in credit card transactions at $50.00 per transaction for average transaction value of ~$500,000. This merchant diversification not only makes the business less sensitive to changing economic conditions in any particular industry but also lowers any adverse effects on financial condition should there be any loss of a merchant.

The report is available here: NETE Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.

Please review important disclosures on our website at http://www.seethruequity.com/.

About Net Element, Inc.

Net Element, Inc. (NASDAQ: NETE) is a global financial technology-driven company specializing in mobile payments and transactional services in emerging countries and in the U.S. The company operates its business through its global mobile payments and transaction processing provider, TOT Group. TOT Group companies include Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012, Aptito, a next generation cloud-based point of sale payments platform, and TOT Money, which has a leading position in Russia and has been ranked as the #1 SMS content provider by Beeline, Russia’s second largest telecommunications operator. NETE has global development centers and high-level business relationships in the U.S., Russia and Commonwealth of Independent States. The company has U.S. headquarters in Miami, Florida and international headquarters in Moscow, Russia.

For more information, visit http://www.netelement.com/.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit http://www.seethruequity.com/.

Contact:

Ajay Tandon
SeeThruEquity
(646) 495-0939

(FIZZ) ‘Refreshes Its’ Momentum

National Beverage Corp. (NASDAQ:FIZZ) today reported results for Fiscal 2014.

“While we exhausted vigorous efforts to overcome much repeated industry challenges, our Fiscal 2014 results were skewed,” stated Nick A. Caporella, Chairman and Chief Executive Officer.

“Painful, Yes – Resilient and Resourceful, we excitingly begin Fiscal 2015,” continued Caporella.

For the fiscal year ended May 3, 2014 –

• Revenues decreased to $641.1 million, off 3.2%
• Net income decreased to $43.6 million, off 7.0%
• Earnings per share decreased to $.93, off 7.9%

“National Beverage is a quality Company, led by its passion to innovate. Vigorous attempts are simultaneously underway to lead the soft drink industry through its evolution to comply with the outcry of regulators and consumers alike. We are and plan to continue leading the way. All areas of our business, including carbonated soft drinks, are growing! Yes, the size of our smile is magnified by our Power+ Sparkling Waters. Our new dynamic creative has resulted in exciting consumer appeal. Keep a watchful eye for LaCroix’s Cúrate with its one-of-a-kind packaging and unique taste! Also, our distinctive change to the new flavors of brand LaCroix are a ‘must’ see and taste,” stated Caporella.

“First quarter is more than on track – May and June have given Fiscal 2015 a passionate start. That’s a YES!!

A lesson worth sharing: silver linings usually accompany challenges, microscopic and often missed. Ours is a vivid confirmation that we own a philosophy that provokes our agility to change direction quickly – while a dynamic metamorphosis is underway in the soft drink industry. Our silver lining places us magnificently in the forefront of it! Indeed, our shareholder value will reflect these opportunistic elements.

Muhammad Ali once said, ‘Taking a punch at certain times . . . may be far better than giving one!’” concluded Caporella.

P.S. We asked on September 5, 2013 to have you judge our results – “trailing twelve months ending July 2014” . . . Well, we are about to see!

National Beverage’s iconic brands are the genuine essence . . . of America.

“Patriotism” – If Only We Could Bottle It!

Fun, Flavor and Vitality . . . the National Beverage Way

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include fluctuations in costs, changes in consumer preferences and other items and risk factors described in the Company’s Securities and Exchange Commission filings. The Company disclaims an obligation to update any such factors or to publicly announce the results of any revisions to any forward-looking statements contained herein to reflect future events or developments.

(OMEX) Over 13.5k Silver/Gold, Coins/Ingots & More Recovered From SS Central America Wreck

Newly Released Inventory Provides First Look at Time Capsule of Gold Rush-Era Treasures

TAMPA, Fla., July 18, 2014  — Odyssey Marine Exploration, Inc. (Nasdaq:OMEX), a pioneer in the field of deep-ocean exploration, has now placed operational reports and inventories of items recovered from the SS Central America shipwreck site on the company’s website at www.shipwreck.net/ssca.php.

These items were initially filed under seal in the United States District Court, Eastern District of Virginia, Norfolk Division. Chief U.S. District Judge Rebecca Beach Smith has allowed the reports to be unsealed and made available to the public.

Odyssey has been working since April 2014 under contract to Ira Owen Kane, the receiver for Recovery Limited Partnership (RLP). RLP is the court-appointed salvor-in-possession of the SS Central America shipwreck.

“This is an iconic American shipwreck, and, as salvor-in-possession, we have a duty to not only recover the remaining valuable cargo and significant items of cultural heritage at the site, but to also share what we learn with the public,” said Kane. “We’re proud of the recovery and scientific work being accomplished on the site. Making the reports, filed with the court, accessible is the first step in allowing the public access to the shipwreck and the heroic stories of her Captain and those who sailed on her final voyage. We continue to engage in a number of fascinating science initiatives, the results of which will be shared with the public and scientific community when complete.”

The inventories detail the items recovered to date, which include gold ingots, nuggets, dust and a wide variety of gold coins from $20 double eagles down through $10, $5, $2.50 and $1 gold coins, as well as California fractional gold, territorials and a wide variety of foreign gold. Additional significant cultural heritage artifacts have been identified and will be recovered.

RLP’s chief scientist Bob Evans served as chief scientist on the 1988-1991 expeditions to the SS Central America and later as curator for the treasure recovered. As one of RLP’s representatives on the project, Evans has been aboard the Odyssey Explorer since operations began in April 2014, cataloguing the gold as it is recovered.

“The variety and quality of the coins being recovered is just astonishing,” commented Evans. “Of course there are spectacular $20 double eagles like we found back in the 80s and 90s. But the wide variety of other denominations makes this year’s recoveries very different from the earlier finds. I have seen what I believe are several of the finest known examples so far. The coins date from 1823 to 1857 and represent a wonderful diversity of denominations and mints, a time capsule of virtually all the coins that were used in 1857.”

Odyssey President and Chief Operating Officer Mark Gordon added: “The operational reports filed with the court provide an overview of the activities conducted during each offshore period. The first two reports detail the pre-disturbance work and the recovery of items visible on the surface in the debris field, as well as initial archaeological excavation activities in the stern area of the shipwreck itself. The next report, which will be filed before July 25, will cover work conducted from mid-June to mid-July. As planned, during this period we made significant progress removing large amounts of coal and overburden to access certain areas of the shipwreck. We’re looking forward to getting back to work at the site in the coming days.”

About the SS Central America

The SS Central America was an 85-meter (280-foot) wooden-hulled, copper-sheathed, three-masted side-wheel steamship launched in 1853 as the SS George Law. Operating during the California Gold Rush era, the ship was in continuous service on the Atlantic leg of the Panama Route between New York and San Francisco, making 43 round trips between New York and Panama. The Central America was caught in a hurricane and sank 160 miles off the coast of South Carolina on September 12, 1857. When she was lost, the SS Central America was carrying a large consignment of gold for commercial parties, mainly in the form of ingots and freshly minted U.S. $20 Double Eagle coins. Because of the large quantity of gold lost with the ship, public confidence in the economy was shaken, which contributed to the Panic of 1857.

The location of the SS Central America shipwreck was confirmed in September 1988 at a depth of 2,200 meters (7,200 feet). Recovery operations were conducted over a four-year period (1988-1991) and a large quantity of commercial gold was recovered from approximately 5% of the shipwreck site during more than 1,000 hours of bottom time.

In 2014, Recovery Limited Partnership, to awarded Odyssey the exclusive contract to conduct an archaeological excavation and recovery of the remaining valuable cargo from the SS Central America shipwreck. Odyssey will receive 80% of recovery proceeds until a fixed fee and a negotiated day rate are paid. Thereafter, Odyssey will receive 45% of the recovery proceeds.

Odyssey was selected for the project by Ira Owen Kane, the court-appointed receiver who represents Recovery Limited Partnership (RLP) and Columbus Exploration LLC (CE). The contract was approved by the Common Pleas Court of Franklin County, Ohio, which has given Mr. Kane responsibility with overseeing the recovery project The United States District Court, Eastern District of Virginia has confirmed RLP as the salvor in possession of the SS Central America shipwreck and that Odyssey may conduct operations at the site on behalf of RLP.

About RLP

Recovery Limited Partnership (RLP) was organized in 1985 as an Ohio limited partnership to finance the SS Central America project. Ira Owen Kane was appointed as the receiver for Recovery Limited Partnership and Columbus Exploration LLC by the Common Pleas Court of Franklin County, Ohio. At the direction of the court, the goal of the receiver is to preserve and operate the business of RLP and Columbus Exploration for the benefit of the investors and their creditors, and to do so by initiating the operations necessary to recover valuable cargo and cultural heritage items that remain on the SS Central America shipwreck site.

About Odyssey Marine Exploration

Odyssey Marine Exploration, Inc. (Nasdaq:OMEX) is engaged in deep-ocean exploration using innovative methods and state of-the-art technology for shipwreck projects and mineral exploration. For additional details, please visit www.odysseymarine.com. The company also maintains a Facebook page at http://www.facebook.com/OdysseyMarine and a Twitter feed @OdysseyMarine. For additional details on Odyssey Marine Exploration, please visit www.odysseymarine.com.

Forward Looking Information

Odyssey Marine Exploration believes the information set forth in this Press Release may include “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the Securities and Exchange Commission on March 17, 2014. The financial and operating projections are based solely on the assumptions developed by Odyssey that it believes are reasonable based upon information available to Odyssey as of the date of this release. All projections and estimates are subject to material uncertainties, and should not be viewed as a prediction or an assurance of actual future performance. The validity and accuracy of Odyssey’s projections will depend upon unpredictable future events, many of which are beyond Odyssey’s control and, accordingly, no assurance can be given that Odyssey’s assumptions will prove true or that its projected results will be achieved.

CONTACT: Media Contact:
         Liz Shows
         Odyssey Marine Exploration, Inc.
         (813) 876-1776 x 2335
         lshows@odysseymarine.com

         Investor Relations Contact:
         Ron Both
         Liolios Group, Inc.
         (949) 574-3860
         OMEX@liolios.com

(RDNT) Acquires Certain Southern California Imaging Assets From HealthCare Partners

LOS ANGELES, July 18, 2014  — RadNet, Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and operated outpatient imaging centers, today reported that effective July 1, 2014, it has acquired certain imaging assets located at eight HealthCare Partners Medical Group facilities. In addition, RadNet has entered into a long-term capitation contract to provide diagnostic imaging services to approximately 65,000 HealthCare Partners Medical Group patients including commercial and managed Medicare and Medicaid enrollees.

As part of the agreement, RadNet acquired routine imaging assets, including x-ray, mammography and ultrasound equipment, located in eight Southern California HealthCare Partners offices in Santa Ana, Fountain Valley, Huntington Beach, Compton, Downey, Long Beach and Anaheim. RadNet has assumed operations at these locations, which continue to service the routine imaging needs of HealthCare Partners patients. In addition, RadNet’s existing facilities, located near these eight offices and convenient to where these HealthCare Partners patients live and work, will offer advanced imaging exams and other services not provided in the eight facilities.

In conjunction with the purchase of these imaging assets, RadNet and HealthCare Partners Medical Group have entered into a five-year capitation arrangement under which RadNet will provide, on an exclusive basis, diagnostic imaging services to approximately 65,000 HealthCare Partners patients who HealthCare Partners manages as part of its commercial and managed Medicare and Medicaid programs. RadNet will perform utilization review and aid HealthCare Partners with the establishment of appropriateness and educational criteria related to their imaging needs.

Dr. Howard Berger, President and Chief Executive Officer of RadNet, noted, “We are delighted to expand our longstanding relationship with HealthCare Partners. In the past, we have worked with several HealthCare Partners Medical Group sites under capitation arrangements, whereby we have exclusively provided imaging services to significant HealthCare Partners-managed patient populations in Southern California. We appreciate the confidence HealthCare Partners has shown in RadNet by effectively outsourcing its imaging needs to us.”

“Capitation remains a core part of RadNet’s business in California. In a post-reform era, healthcare will continue to migrate towards capitation and other business models whereby efficiently-managed, high quality providers will assume the risk associated with healthcare utilization and provide patient care for fixed compensation. The traditional fee-for-service model of healthcare has led to the rising cost of health insurance, inefficient providers and over-utilization of care. I am convinced that the capitation model, which is more advanced in California than in most other states, will be an effective model for healthcare reform across the country. RadNet and HealthCare Partners are well positioned to benefit from this trend,” added Dr. Berger.

About RadNet, Inc.

RadNet, Inc. is the largest provider of fixed-site outpatient diagnostic imaging services in the United States through a network of 250 owned and/or operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, New Jersey, New York and Rhode Island. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 6,000 employees. For more information, visit http://www.radnet.com.

About HealthCare Partners

HealthCare Partners, LLC, a subsidiary of DaVita HealthCare Partners, manages HealthCare Partners Medical Group along with organizations in Nevada, Florida, Arizona, and New Mexico. HealthCare Partners Medical Group has been named a top-performer for ten years in a row by the Integrated Healthcare Association (IHA), and has been recognized by health plans and business groups for medical leadership, the high quality of medical care delivered, operational effectiveness, and high rates of patient satisfaction. With more than 1,800 employed and affiliated primary care physicians and more than 4,500 employed and contracted specialists, HealthCare Partners Medical Group cares for patients in Los Angeles, Long Beach, South Bay, the Pasadena/San Gabriel Valley area, the San Fernando and Santa Clarita Valleys, and Orange County. In addition to primary care doctors’ offices, HealthCare Partners Medical Group provides medical services through urgent care centers, and offers a wide variety of support programs such as 24-hour telephone support, electronic medical records, health education classes, and special programs for chronic conditions. For more information, please visit www.healthcarepartners.com

CONTACT: RadNet, Inc.
         Mark Stolper, 310-445-2800
         Executive Vice President and Chief Financial Officer

(IG) To Hold Conference Call For 2nd Quarter 2014 Results

BUENA, N.J., July 18, 2014 — IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 24, 2014 to discuss the 2nd quarter 2014 results.

The Company invites you to listen to the call by dialing 1-877-870-4263. International participants should call 1-412-317-0790. Canadian participants should call 1-855-669-9657. Participants should ask to be joined into the IGI Laboratories, Inc. call.

This call is being webcast by MultiVu (a PR Newswire Company) and can be accessed in the Investor Relations Section of IGI’s website at www.igilabs.com.

About IGI Laboratories, Inc.

IGI Laboratories is a generic topical pharmaceutical company. We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.